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A B S T R A C T
1

A B S T R A C T
Commonly used transgenic mouse models mimic Alzheimer´s disease (AD) to some
extent but do as well display differences compared to the human AD phenotype. Grow-
ing evidence indicates that N-terminally truncated Aβ isoforms, which are underrep-
resented in common murine models, represent a key player in AD. These peptides
are abundant in AD brains and have increasingly gained attention during the past
years. It has been suggested that the equilibrium of aggregation is shifted towards
the more toxic low-molecular weight oligomeric assemblies due to N-terminal trunca-
tion of Aβ, thereby triggering neurodegenerative processes. In this study, characteriza-
tion of a recently developed monoclonal antibody, NT4X-167, revealed its engagement
with N-terminally truncated AβpE3−X and Aβ4−X. We also showed the propensity
of Aβ4−X to adopt a distinct oligomeric conformation. Analysis of a newly created
homozygous 5XFAD mouse strain with NT4X-167 revealed early intracellular accumu-
lation of Aβ4−X in this model, preceding other N-truncated isoforms, AβpE3−X and
Aβ5−X. Investigation of homozygous 5XFAD mice revealed a gene-dose dependence
of the neuropathological and behavioral phenotype. Homozygous 5XFAD might espe-
cially facilitate the analysis of intracellular Aβ, truncated isoforms in particular. Con-
sidering the consensus that Aβ is a key player on one hand, and the failure of recent
anti-Aβ immunotherapeutic trials in AD on the other hand, there is an urgent need to
find new therapeutic targets and strategies. In the course of this, it has been proposed
that targeting N-truncated Aβ might offer therapeutic advantage. In order to explore
the therapeutic potential of passive anti-N-truncated Aβ immunization, a comparative
study with three monoclonal antibodies (NT4X-167, 9D5, 1-57) in 5XFAD was conduc-
ted in this study. As NT4X-167 showed a significant effect, it can be concluded that this




I N T R O D U C T I O N

1
I N T R O D U C T I O N
1.1 alzheimer‘s disease
Auguste Deter, whose case was reported by Alois Alzheimer in the year 1906 at the
37th meeting of the Society of Southwest German Psychiatrists (Tübingen, Germany)
was the first patient described with a characteristic combination of symptoms. She
displayed character and mood changes as well as progressive memory and language
deficits and loss of orientation. After her death, A. Alzheimer found the brain to be
atrophic, with intracellularly accumulated neurofibrils and extracellular miliary bodies
(plaques) (Alzheimer, 1907). After A. Alzheimer, the disease he had described was
named Alzheimer´s Disease later on.
1.2 clinical aspects of alzheimer‘s disease
1.2.1 Epidemiology
The World Health Organization estimates the number of people that suffered from
dementia in the year 2010 to be 36 million people. This number is believed to increase to
66 million by the year 2030 and 115 million by 2050. The global cost of dementia in 2010
is estimated to $ 604 billion. This amounts to 1 % of the global gross domestic product,
a number underlining the impact demential diseases have on society and economy.
AD is the most common form of dementia, accounting for 60 - 70 % of these numbers
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(World Health Organzation, 2012). According to the German Alzheimer´s Association
(Deutsche Alzheimer Gesellschaft), in 2014 1.4 million people were suffering from AD
in Germany.
1.2.2 Risk Factors for Alzheimer´s Disease
Two forms of AD are described: An inherited (familial) form which accounts for ap-
proximately 1 % of the disease cases (Zetterberg and Mattsson, 2014), and a majority of
sporadic cases. The major risk factor to develop AD is age (Blennow et al., 2006). One
out of eight people older than 65 years and 45 % of the people older than 85 suffer
from AD, but despite this high prevalence of the disease in the elderly it is not part
of the normal aging process. Besides aging, epidemiological studies have suggested a
variety of risk factors for sporadic AD. Carrying at least one copy of the ApoE4 allel
increases the risk of developing AD (Corder et al., 1993). Other risk factors include
vascular diseases such as atherosclerosis, hypercholesterolemia, coronary heart disease
and heart failure (Kivipelto et al., 2001, 2005; Qiu et al., 2006), obesity, smoking, type
II diabetes (Kivipelto et al., 2005; Leibson et al., 1997; Prince et al., 1994). In addition,
head injury and traumatic brain injuries could be risk factors for AD (McCullagh et al.,
2001; Plassman et al., 2000; Sivanandam and Thakur, 2012). On the other hand, there
are studies connecting a healthy, cognitively and physically active lifestyle as well as
certain dietary habits with a reduced risk of AD (Fratiglioni et al., 2004; Gu et al., 2010;
Hall et al., 2009).
1.2.3 Progression of the Disease
The progression of AD is slow and results in progressive cognitive decline with memory
deficits, often in combination with personality or mood changes (Alzheimer´s Associ-
ation 2012). According to Holtzman et al. (2011), the average development from mild/
moderate AD to a severe clinical phenotype occurs within 7-10 years.
In 2011, the Alzheimer´s Association together with the National Institute of Aging
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(NIH) proposed new guidelines for the classification of AD. A division into three
stages was suggested: Preclinical AD, mild cognitive impairment due to AD and de-
mentia due to AD (Albert et al., 2011; Jack et al., 2011; McKhann et al., 2011; Sperling
et al., 2011). In preclinical AD, no symptoms are observed, whereas patients with mild
cognitive impairment display a beginning cognitive decline. The conversion of these
patients into the dementia phenotype occurs with a rate of 10-15 % per year. This con-
version defines the mild cognitive impairment as an early stage of AD for this patients
(Petersen, 2004; Visser et al., 2005). AD leads to severe cognitive decline, motor impair-
ment and loss of visio-spatial abilities. This accumulation and progressive severity of
symptoms is ultimately fatal and leads to death subsequently (Holtzman et al., 2011;
Wada et al., 2001).
1.3 pathological hallmarks of alzheimer‘s disease
1.3.1 Amyloid Plaques
One of the major pathological hallmarks of AD is the formation of extracellular depos-
its (plaques) composed of the Amyloid-beta peptide (Aβ) that is derived from cleavage
of Amyloid-Precursor-Protein (APP) (Holtzman et al., 2011; Serrano-Pozo et al., 2011).
The particular isoforms are termed in regard to the amino acid sequence: AβX1−X2,
Amyloid-beta peptide ranging from N-terminal amino acid X1 to C-teminal amino
acid X2. Two distinguishable types of plaques are found in human AD brain: Diffuse
plaques and neuritic plaques. Of these types only neuritic plaques are strongly stained
by Thioflavin S or Congo Red, dyes that interact with β-sheeted protein assemblies,
indicating a fibrillar and more dense structure (Serrano-Pozo et al., 2011). The amyloid
deposition typically starts in the neocortex and affects hippocamus and amygdala later.
In the end stage of AD, neuritic plaques are additionally found in subcortical structures
such as the brain stem (Arnold et al., 1991; Serrano-Pozo et al., 2011; Thal et al., 2002).
In the vicinity of neuritic plaques, a range of pathological alterations is observed, such
as neuron and synapse loss, astro- and microgliosis and neuritic dystrophies (Holtz-
man et al., 2011; Lenders et al., 1989; Masliah et al., 1990; Pike et al., 1995a; Selkoe,
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2011; Urbanc et al., 2002). The observation that plaques, mainly of the diffuse subtype
and with almost no detectable neuritic dystrophy, are also present in healthy older in-
dividuals led to the hypothesis that an increase of the plaque load is associated with
preclinical AD (Dickson et al., 1992; Knopman et al., 2003; Vlassenko et al., 2011). How-
ever, although plaques are a diagnostic hallmark of AD, the absolute plaque burden
correlates with cognitive decline and disease stage poorly (Arriagada et al., 1992; Gian-
nakopoulos et al., 2003; Villemagne et al., 2011). In addition, roughly 80 % of the AD
patients show the symptom of amyloid deposition in blood vessels, called Cerebral
Amyloid Angiopathy (CAA).
1.3.2 Neurofibrillary Tangles
Already the initial report of A. Alzheimer (Alzheimer, 1907) mentioned the second
neuropathological hallmark of AD, intracellular Neuro-fibrillary Tangles (NFT) consisting
of hyper-phosphorylated Tau protein organized in paired helical filaments (Grundke-
Iqbal et al., 1986; Kidd, 1963; Lee et al., 1991). Tau is a protein ubiquitously expressed
in all nucleated cells and highly abundant in neurons. In its physiological function,
Tau is involved in the organization of microtubules (Drechsel et al., 1992; Gustke et al.,
1994; Weingarten et al., 1975; Witman et al., 1976). Its hyper-phosphorylation results
in reduced tubulin binding and a higher propensity to form paired helical filaments
(Alonso et al., 1996; Holtzman et al., 2011). It has been reported that the NFT forma-
tion in AD brain is a better correlate for the clinical phenotype than plaque formation
(Holtzman et al., 2011). For diagnosis and staging of AD, Tau is crucial (Arnold et al.,
1991; Braak and Braak, 1991), but Tau aggregation and NFT formation appear later
than amyloid deposition in the development of AD (Galimberti and Scarpini, 2012).
1.3.3 Inflammation
Another pathological feature of AD are inflammatory reactions in the brain. In the vi-
cinity of neuritic plaques, activated microglia and astrocytes are found, which suggests
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that Aβ acts as a trigger for inflammation (Itagaki et al., 1989; Krause and Muller, 2010;
Pike et al., 1995a). In response to activation, microglia and astrocytes release proinflam-
matory signal molecules, complement factors, chemokines and cytokines (Rubio-Perez
and Morillas-Ruiz, 2012; Tuppo and Arias, 2005). Several studies suggest that glial
cells surrounding neuritic plaques engulf and process Aβ (Koenigsknecht-Talboo et al.,
2008; Meyer-Luehmann et al., 2008). It was in consequence proposed that activated
glial cells contribute to Aβ clearance and that this might be beneficial for treatment of
AD (Bard et al., 2000; DeMattos et al., 2012). For instance, DeMattos et al. (2012) have
reported that treatment with antibodies exhibiting maximal phagocytosis effector func-
tion is most efficient in removing deposited Aβ from murine brain. However, it has
been questioned if microglia are capable of efficient Aβ degradation (Majumdar et al.,
2007; Paresce et al., 1997). It is unclear whether inflammatory responses are generally
detrimental in AD or if some aspects of inflammation might be beneficial (Weninger
and Yankner, 2001).
1.3.4 Brain Atrophy and Neuron Loss
Brain atrophy is a prominent feature of an AD brain, but also of other demential
diseases such as frontotemporal dementia or vascular dementia (Blennow et al., 2006).
The regions in which atrophy is observed in AD include the medial temporal lobe, hip-
pocampus and amygdala, the inferior temporal as well as the superior and middle
frontal gyri, but not the inferior frontal and orbifrontal gyri (Blennow et al., 2006;
Duyckaerts et al., 2009; Halliday et al., 2003). Along with others, Kril et al. (2004)
have found a strong correlation of neuron number and hippocampal/brain volume,
indicating that these are somehow connected. It has further been reported that MRI
brain imaging in order to assess hippocampal atrophy can give good indication of
the progression from mild cognitive impairment to AD (Jack et al., 2005; Jagust, 2006).
What causes the atrophy/neuron loss observed in AD is subject to an ongoing discussion.
Some research groups reported a correlation of brain atrophy with NFTs, whereas oth-
ers suggested that intracellular accumulation of aggregated Aβ plays an important role
(Bayer and Wirths, 2010; Gomez-Isla et al., 1997; Haass and Selkoe, 2007).
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As it is challenging to confirm neuron loss, it is unclear whether it is essential in AD
(Duyckaerts et al., 2008). However, brain neuronal loss is observed in some transgenic
murine models of AD (Bouter et al., 2014; Casas et al., 2004; Christensen et al., 2008,
2010a; Jawhar et al., 2012; Meissner et al., 2014; Oakley et al., 2006; Saul et al., 2013;
Schmitz et al., 2004; Wirths and Bayer, 2010).
1.4 diagnosis of alzheimer‘s disease
Currently, an exact diagnosis of AD ist only possible post mortem. This diagnosis is
essentially based on the analysis of the neuropathological hallmarks mentioned above,
i.e. amyloid plaques and NFTs in the brain (Braak and Braak, 1991; McKhann et al.,
1984).
Therefore, cognitive impairment and behavioral alterations are assessed to make an
assumption whether a person will eventually be diagnosed with AD. To this end,
patients presenting with mild cognitive impairment undergo physical and cognitive
assessement by various testing procedures such as the Mini-Mental Stage Examination
(Folstein et al., 1975), the Clock-Drawing Test (Aprahamian et al., 2010; Sunderland
et al., 1989) or the Cambridge Cognitive Examination (Martinelli et al., 2014; Schmand
et al., 2000). For a probable diagnosis of AD, deficits that affect the patient in daily
activities are crucial (American Psychiatric Association, 1995). Besides memory impair-
ment symptoms such as agnosia, aphasia, apraxia or deficits in executive functions
are required (Waldemar et al., 2007). This diagnosis can be supported by neuroima-
ging employing Magnetic Resonance Tomography, Computer Tomography, or Positron-
Emission Tomography (Ballard et al., 2011; Blennow et al., 2006; Perrin et al., 2009;
Schroeter et al., 2009). Furthermore, analysis of biomarkers in the cerebrospinal fluid
has been established for diagnosis of mild cognitive impairment and AD. Reduced
levels of AβX−42 and increased levels of Tau and phospho-Tau support a diagnosis of
AD (Fiandaca et al., 2014; Mattsson et al., 2009; Perrin et al., 2009).
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1.5 the amyloid precursor protein
Aβ is derived from sequential cleavage of APP (Korenberg et al., 1989), a type-1 trans-
membrane glycoprotein (Puzzo et al., 2014) belonging to the amyloid-precursor-like
protein family. Although in general the members of this family are structurally highly
conserved, they exhibit large hetrogeneity in the Aβ region (Selkoe, 2001). At least
four different mRNAs encoding APP that result from alternative splicing are known.
Together with different post-translational modifications, these result in a variety of iso-
forms expressed in different types of tissues. These isoforms are named by the number
of amino acids: The three major forms APP770, -751, and -695 are expressed in neuronal
cells, with the latter being most frequently expressed (Selkoe, 2001).
1.5.1 Processing
APP is physiologically processed by proteases, resulting in a variety of released pep-
tides. Two alternative pathways of this processing have been described (De-Paula et al.,
2012). In the non-amyloidogenic pathway, APP is cleaved within the Aβ region by
several α-secretases relasing the so-called sAPPα fragment which has been suggested
to have neuroprotective activity to the extracellular space (Chow et al., 2010; Esch et al.,
1990; Furukawa et al., 1996; Mattson, 1997; Sisodia et al., 1990). Various enzymes have
been proposed to function as α-secretase, including ADAM9, ADAM10, ADAM17,
ADAM19 or TACE (Haass, 2004; Haass et al., 2012). Within the cell membrane, a
C-terminal fragment, C83, remains and is further cleaved by γ-secretase, releasing the
so-called p3 peptide and the APP intracellular domain (AICD) (Carrillo-Mora et al.,
2014; Querfurth and LaFerla, 2010).
Amyloidogenic Pathway
The mechanism resulting in release of Aβ is the so-called amyloidogenic pathway
(De-Paula et al., 2012). Here, APP is first cleaved at the N-terminus of the Aβ sequence
by the aspartyl protease site APP cleaving enzyme 1 which liberates the N-terminal
13
Figure 1.1
APP Processing. In the non-amyloidogenic pathway, APP is first cleaved by α-secretase within
the Aβ domain and then further by γ-secretase. Peptides released are sAPPα, the APP intracel-
lular domain (AICD) and the p3 fragment. No Aβ is produced. In the amyloidogenic pathway,
APP is processed by aspartyl protease site APP cleaving enzyme 1 (BACE1) in the first step
and then by γ-secretase in the second step. The amyloidogenic cleavage of APP results in the
release of Aβ, sAPPβ and AICD.
domain sAPPβ (Vassar et al., 1999). The membrane-bound fragment remaining (C99)
is further processed by γ-secretase. In consequence, Aβ and the intracellular domain
of APP are released (Annaert and De Strooper, 2002).
The γ-secretase, essentially involved in the amyloidogenic pathway, is a complex
protease composed of several membrane-bound proteins, presenilin-1 or presenilin-2,
nicastrin, anterior pharynx defective-1, presenilin enhancer protein-2 and cluster of
differentiation 147 (Kaether et al., 2006; Zhou et al., 2006). The non-amyloidogenic
pathway is located to the cell surface, whereas the amyloidogenic cleavage mainly
takes place in endocytic organelles (Thinakaran and Koo, 2008). It has further been
shown that up-regulation of α-secretase activity results in lower production of Aβ in
subcellular compartments (Nitsch et al., 1992; Postina et al., 2004). This indicates that
the regulation of APP processing is of importance for the development and progression
of AD.
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1.6 the amyloid cascade hypothesis
Several hypotheses have been proposed to explain AD. A main step of AD research
was the identification of APP, made possible by investigation of Aβ-containing blood
vessels in CAA and amyloid plaques (Glenner and Wong, 1984; Kang et al., 1987; Mas-
ters et al., 1985). The dominant view since 1991 has been that Aβ deposition in plaques
is the main event in AD, triggering the neurodegenerative processes (Duyckaerts et al.,
2009; Hardy and Allsop, 1991; Selkoe, 1991) (Figure 1.2, page 16). However, since amyl-
oid plaque burden and cognitive deficits correlate poorly in humans (Price and Morris,
1999) and even animal models (Moechars et al., 1999; Schmitz et al., 2004), this Amyloid
Hypothesis was controversely discussed.
Genetic studies on familial AD lead to the identification of numerous mutations in
the APP, presenilin-1 and presenilin-2 genes as underlying cause of the inherited form
of AD. All of these mutations cause an early-onset AD with 100 % prevalence and
share the common effects of altering Aβ levels and increasing plaque deposition (Ber-
tram et al., 2010; Pimplikar, 2009). Down syndrome patients, who carry an additional
chromosome 21 where the APP gene is located, exhibit abundant plaque and intra-
cellular NFT pathology (Rumble et al., 1989; Schupf and Sergievsky, 2002). Recently,
a rare genetic variant of the APP gene that leads to reduced Aβ levels and risk of
AD was discovered (Jonsson et al., 2012). The most important genetic risk factor for
sporadic AD, apolipoprotein E ε4, is furthermore connected with increased Aβ depos-
ition and reduced clearance from the brain (Bickeboller et al., 1997; Castellano et al.,
2011). All these observations support the amyloid cascade hypothesis.
Unlike mutations in the APP and Presenilin (PS) genes, mutations in the Tau gene
lead to other neurodegenerative diseases like frontotemporal dementia whose clinical
phenotypes are different from these of AD. It has therefore been suggested that the
formation of NFTs is not the initial event in AD but likely occurs in response to Aβ
aggregation (Goedert and Jakes, 2005; Hutton et al., 1998; Iqbal et al., 2005).
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Figure 1.2
Classic and modified amyloid cascade hypothesis. The classic amyloid cascade hypothesis
regards the extracellular formation of amyloid plaques as the main event in AD. In contrast,
according to the modified amyloid cascade hypothesis the intracellular accumulation of Aβ is
considered the key event triggering the pathologic cascade in AD.
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1.6.1 Intracellular Amyloid Hypothesis
As early as in Masters et al. (1985), the first report on intracellular Aβ was published,
and it has been shown later that, prior to formation of plaques and NFTs, Aβ is found
intracellularly in brain regions that degenerate in AD (Fernandez-Vizarra et al., 2004;
Gouras et al., 2010). Along these lines, it has been found that Down syndrome patients
lacking amyloid plaques show intracellular Aβ in the brain (Gyure et al., 2001; Mori
et al., 2002). Haass and Selkoe (2007) suggested intracellular Aβ accumulation as the
triggering event of neurodenerative alterations in the brain.
The authors proposed that amyloid plaques might serve as a source or reservoir
for neurotoxic Aβ-oligomers, which might affect synaptic structure and plasticity. Be-
sides intracellular cleavage of APP, another possible source of intracellular Aβ is re-
uptake from the extracellular space (Wirths et al., 2004). The fact that plaques possibly
represent a major source of toxic Aβ oligomers has later been plausibly demonstrated
by Martins et al. (2008). Within this modified or intracellular amyloid hypothesis (Figure 1.2,
page 16), it has been furthermore suggested that intracellular Aβ aggregation precedes
the formation of plaques and other pathologic symptoms of AD (Wirths et al., 2004).
The pathologic relevance of intracellular Aβ has been demonstrated in mouse models
that show little or no extracellular amyloid deposition but behavioral deficits (Bouter
et al., 2013; Wittnam et al., 2012) and models with plaques that develop a substantial
neuron loss in regions where Aβ accumulates intracellularly (Christensen et al., 2010a;
Jawhar et al., 2012; Oakley et al., 2006). It has been shown that plaques are present
some ten years before the first memory complaints in patients and that plaque depos-
ition is virtually at maximal levels by the time of diagnosis (Jack et al., 2010; Morris
and Price, 2001; Price et al., 2009). This finding indicates that further plaque deposition
is not connected to the progression of the disease. In summary, all mentioned studies




The Aβ peptides observed in human brain are a heterogenous mixture of various iso-
forms. The major forms found are Aβ1−42 and Aβ1−40, the previous representing the
major constituent of amyloid plaques, the latter is most abundant in amyloid deposits
in blood vessels CAA (Iwatsubo et al., 1994; Suzuki et al., 1994). Besides these major
species, commonly termed full-length Aβ, numerous C- and N-terminally divergent
variants have been described. These include Aβ1−37/38/39 (Portelius et al., 2012; Rein-
ert et al., 2014; Wiltfang et al., 2002) as well as Aβ C-terminally exceeding amino acid
42 (Esh et al., 2005; Van Vickle et al., 2008; Welander et al., 2009). Of these, AβX−43 was
detected in plaques of both mouse models and human AD, for the latter in considerable
amount (Welander et al., 2009). Recently, Kaneko et al. (2014) reported eight novel Aβ-
like peptides that start and end before the β- and γ-secretase cleavage site, the longest
of which consisting of amino acids 663-711 of the APP sequence. Aβ variants with vary-
ing terminal end lengths have been described with different aggregation propensity,
oligomer stability and structure, resistance to proteolytic degradation and neurotoxic
activity (e.g. in Bouter et al. (2013); Jan et al. (2008); Jarrett et al. (1993); Pike et al.
(1995b); Russo et al. (2002); Wirths et al. (2010c)).
1.7.1 N-terminally Truncated Amyloid-beta
In addition to C-terminally truncated Aβ, a variety of N-terminally deviant isoforms
has been described (Bayer and Wirths, 2014; Masters et al., 1985; Mori et al., 1992; Selkoe
et al., 1986; Sergeant et al., 2003). These ragged N-termini are believed to result from dif-
ferential cleavage and/or proteolytic activity after secretion. Besides aspartyl protease
site APP cleaving enzyme 1 which has been shown to cleave between Tyr-10/Glu-11
in addition to cleavage before Asp-1 (Vassar et al., 1999), several other peptidases have
been proposed to be involved in the generation of N-truncated Aβ. This includes the en-
zymes meprin-β, producing Aβ starting at residue 2 (Bien et al., 2012), and neprilysin
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(neutral endopeptidase, a zinc-metalloprotease) that cleaves between Arg-2/Glu-3, Glu-
3/Phe-4, Arg-5/His-6 of the Aβ sequence and myelin basic protein cleaving between
Phe-4/Arg-5 (Howell et al., 1995; Iwata et al., 2001; Liao et al., 2009) as well as plasmin
which is involved in formation of Aβ starting at His-6 (Tucker et al., 2000; Van Nos-
trand and Porter, 1999). N-terminal truncation makes the resulting Aβ peptides more
prone to aggregate (Pike et al., 1995b), which probably promotes plaque formation in
vivo (Soto et al., 1995). Aβ with ragged N-termini is highly abundant in human AD
brain (Kawarabayashi et al., 2001; Portelius et al., 2010; Saido et al., 1995).
Amyloid-beta Starting with a Pyroglutamate-Modified Residue three (Glu-3)
During the past years, it was in particular Aβ starting with a pyroglutamate-modified
residue 3 (AβpE3−X) that has gained considerable attention. Mori et al. (1992) repor-
ted that roughly 15-20 % of Aβ peptides are N-terminally pyroglutamate-modified.
This isoform combines characteristic properties deviant from N-terminally intact Aβ: It
readily aggregates to oligomeric assemblies, exerts higher neurotoxicity than Aβ1−40/42
and is highly resistant to degradation (Kuo et al., 1997; Russo et al., 2002; Wirths et al.,
2010c). Its high abundance in AD and Down syndrome patients suggests that it may
play an important role in the disease, and it has been found to be a main constitu-
ent of highly condensed amyloid plaque cores (Frost et al., 2013; Miller et al., 1993).
However, the role of AβpE3−X in AD and the possible mechanism of action are subject
to ongoing discussion: It has been proposed that AβpE3−X oligomers act as a seed
in AD and thereby promote plaque formation (Schlenzig et al., 2009) and it has been
suggested that AβpE3−X might act in a prion-like matter, promoting toxicity by im-
printing its conformation onto other Aβ assemblies (Nussbaum et al., 2012). Others see
pyroglutamate-modified Aβ as restricted to plaques (DeMattos et al., 2012). AβpE3−X
has been suggested as a therapeutic target in AD and anti-AβpE3−X-antibodies have
been reported to be capable of influencing the progression of pathological alterations
in mouse models of AD (DeMattos et al. (2012); Frost et al. (2012); Wirths et al. (2010c)
see also 1.9.3, page 27).
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Amyloid-beta Starting at Residue Four (Phe-4)
Another species of N-terminally truncated Aβ that is abundant in human AD brain is
Aβ4−X. As early as in 1985 it was discovered that these isoforms are a component of
patients brain amyloid deposits (Masters et al., 1985). In 2006, Lewis et al. (2006) repor-
ted that Aβ4−42 is relatively abundant in AD, aged controls and vascular dementia. On
the whole, Aβ4−X has not gained much attention and therefore less is known about
its function and properties. Aβ4−42 is less abundant according to Miller et al. (1993)
and Näslund et al. (1994), whereas the results from Portelius et al. (2010) support the
findings of Masters et al. (1985) concluding that it is a major component in human AD.
Miravalle et al. (2005) found Aβ4−42 to be a major constituent of cotton wool plaques in
familial AD patients with the V261I mutation in the presenilin-1 gene. A recent study
showed that Aβ4−42 rapidly assembles to oligomers and is as toxic as Aβ1−42 and
AβpE3−42 (Bouter et al., 2013). These studies indicate that Aβ4−42 is important for AD,
although the precise amount of Aβ starting at Phe-4 in AD remains unclear.
Amyloid-beta Starting at Residue Five (Arg-5)
The knowledge about another isoform with ragged N-terminus, Aβ5−X, is even scarcer.
It is present in AD and was suggested to be the result of alternative cleavage of APP
involving caspase activity (Murayama et al., 2007). The role of Aβ5−X and its toxicity
remain unclear (Bayer and Wirths, 2014).
1.8 mouse models of alzheimer‘s disease
A variety of transgenic murine models was described after the discovery of mutations
that lead to familial AD. The alterations in these models resemble pathologic features
of AD such as amyloid deposition, neuron loss, aggregation of phosphorylated Tau
and behavioral and/or memory deficits. All these models rely on overexpression of
human APP and/or presenilin-1/2 with at least one familial AD mutation. They differ
noticeably regarding their phenotype, which is likely to reflect different promotors
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used, the genetic background (mouse line), the transgene doses and differring effects
of mutations introduced with the transgene(s) (Elder et al., 2010).
1.8.1 APP-based Models
The first successful generation of a transgenic AD model was reported by Games
et al. (1995) who created the PDAPP model, in which a Platelet-derived groth factor-
β (PGDF) promotor-driven human APP transgene with the mutation V717F was intro-
duced. PDAPP exhibits an age-dependent deposition of Thioflavin S-positive amyloid
plaques starting at the age of 6 months. Furthermore, the model develops dystrophic
neurites, astro-/microgliosis in proximity to the amyloid plaques, age-related learn-
ing impairment and synapse loss (Chen et al., 2000; Dodart et al., 2000; Games et al.,
1995; Reilly et al., 2003). In a similar approach, a transgenic line overexpressing hu-
man APP with the K670N/M671L (Swedish) mutation under a hamster Prion Pro-
tein (PrP) promotor was described by Hsiao et al. (1996): The Tg2576 model develops
age-dependent amyloid Thioflavin S-postive deposits between 9 and 10 months of age,
gliosis and learning deficits and has been widely used for research (Elder et al., 2010).
In addition to the PDAPP and Tg2576 models, several other APP-based models have
been developed and characterized subsequently. They all show elevated production
of Aβ, gliosis and dystrophic neurites. Other features such as behavioral deficits have
been frequently described (Elder et al., 2010). Most recently, a human APP Knock-in
mouse model has been described. This model develops amyloidosis and memory de-
ficits without expressing the mutant APP beyond endogenous levels (Nilsson et al.,
2014).
1.8.2 Models with Presenilin Mutations
As mutations in the APP gene cause familial AD, so do mutation in the PS genes 1 and
2. These proteins are constituents of the γ-secretase complex involved in amyloido-
genic cleavage of APP. Consequently, human mutant PSs have been overexpressed in
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transgenic mice to study their effects. Mouse models harboring only these transgenes
do not develop any plaques but show elevated levels of AβX−42. When crossed to APP
overexpressing lines, the PS mutations cause an earlier onset of pathology and more
abundant plaque deposition (Elder et al., 2010). Well-characterized lines combining ef-
fects of both mutant APP and PS are the APP/PS1∆E9 model (Borchelt et al., 1997),
the APP/PS1KI model (Casas et al., 2004) and the 5XFAD model (see 1.8.2, page 22).
Research on these lines contributed considerably to the better understanding of intra-
cellular Aβ, neuron loss and behavioral phenotype (Casas et al., 2004; Christensen et al.,
2010a; Jawhar et al., 2012; Oddo et al., 2003; Wirths and Bayer, 2012; Wirths et al., 2009).
It is not understood why the mere expression of PS transgenes only poorly resembles
the AD features (Elder et al., 2010).
The 5XFAD Mouse Model
Transgenic mice (Tg6799) expressing five familial AD mutations (5XFAD) were first de-
scribed by Oakley et al. (2006). This strain expresses human Amyloid-Precursor-Protein
(isoform APP695) and PS-1 with a total number of five familial mutations known to
cause familial AD in humans under a murine Thy-1 promoter (Moechars et al., 1996;
Oakley et al., 2006; Vidal et al., 1990): three mutations in the human APP locus, Swedish
(K670N, M671L), Florida (I716V) and London (V717I) mutation, as well as two PS-1
mutations, M146L and L286V. When hemizygous, these mice display intraneuronal Aβ
accumulation and extracellular plaque pathology at the age of 6-8 weeks (Oakley et al.,
2006). At the age of approximately 6 months, female mice show behavioral impairment
and working memory deficits. At the age of 12 months, neuron loss in cortical layer V
and robust reference memory impairment are found. The neuron loss in cortical layer
V has been linked to the accumulation of intracelluar Aβ (Jawhar et al., 2012; Oakley
et al., 2006). The 5XFAD model develops its phenotype rapidly and displays import-
ant major features of AD. 5XFAD has been widely used and has been employed for
several preclinical studies investigating treatment effects on the behavior phenotype
(Aytan et al., 2013; Bhattacharya et al., 2014; Cho et al., 2014; Fiol-deRoque et al., 2013;
Hillmann et al., 2012; Wirths et al., 2010c).
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Other Models
Besides APP and APP/PS transgenic models, several other models have been de-
veloped for AD research. Of particular importance are models investigating the effects
of N-truncated isoforms expressed exclusively without relying on APP overexpression
and processing: The TBA42 and the Tg4-42 model (Bouter et al., 2013; Meissner et al.,
2014; Wittnam et al., 2012), develop neuron loss and behavioral/memory deficits des-
pite lacking abundant amyloid deposition in the brain. Therefore, they support the
hypothesis that intracellular soluble aggregates of Aβ play a key role in AD (see also
1.8.3, page 24). Another, non-transgenic model addressing the risk factor diabetes mel-
litus type II is the icv-STZ model that was described with some important pathological
features of AD including memory impairment (Chen et al., 2012, 2013; de la Monte and
Wands, 2008; Salkovic-Petrisic et al., 2006). Although the relevance of murine, mutant
APP/PS transgenic models is sometimes questioned since these are clearly associated
with the minor fraction of approximately 1 % familial AD cases, they are widely
employed. This is due to the fact that rodent species do not develop any amyloid-
related pathology spontaneously, but offer important time and cost advantages over
other mammal models such as canines or non-human primates. Besides the icv-STZ
model mentioned above, it was recently proposed that the Tg4-42 mouse represents a
better model for sporadic AD rather than APP/PS-based models because it does not
rely on any mutation (Bouter et al., 2014). However, both the icv-STZ and the Tg4-42
model, do share certain pathologic alterations with various mutation-based models
(Bouter et al., 2014; Chen et al., 2013). Furthermore, as do all other models currently
available, they do not fully resemble the complex pathological alterations ongoing in
human sporadic or familial AD. Thus, due to the convincing resemblance of major AD
features, abundant plaque deposition and expression of a heterogenous Aβ peptide
pool, mutation-based transgene models must still be considered relevant for sporadic
AD.
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1.8.3 N-terminally Truncated Amyloid-beta in Murine Models
N-terminally ragged Aβ has not only been observed in brains of AD patients but also
in murine models of AD: AβpE3−X, Aβ4−X and Aβ5−X have been shown to be pro-
duced in the 5XFAD model (Jawhar et al., 2012; Wittnam et al., 2012). Also, several
N-truncated isoforms of Aβ have been reported in the APP/PS1KI model, including
Aβ4−X/Aβ5−X detectable from the age of 2.5 months and AβpE3−X from 6 months
(Casas et al., 2004) and in the Tg2576 model (Kawarabayashi et al., 2001). These studies
have been further supported by a comparative study by Frost et al. (2013) who assessed
AβpE3−X-immunoreactivity semi-quantitatively in 11 different mouse models of AD,
including 5XFAD, APP/PS1∆E9, and Tg2576. Within an approach of passive immun-
ization, an antibody raised against AβpE3−X was further reported to strongly label
amyloid plaques in the PDAPP model (DeMattos et al., 2012). Several studies have
demonstrated that AβpE3−X is most abundant in the amyloid plaque cores (Frost et al.,
2013; Härtig et al., 2010; Jawhar et al., 2012; Maeda et al., 2007).
Recently generated mouse models support further in-vivo toxicity of N-truncated
Aβ: In TBA42 (expressing AβpE3−42) and Tg4-42 (expressing Aβ4−42) mice, the mere
expression of the respective ragged isoform led to intracellular accumulation of the
peptides and subsequently to behavior/memory deficits and massive loss of neurons
(Bouter et al., 2013; Meissner et al., 2014; Wittnam et al., 2012).
In addition to the APP/PS1KI model (Casas et al., 2004), Aβ5−42 was very recently
reported for the 5XFAD and another (3xTg) model (Guzman et al., 2014), but without
any evidence of intracellular accumulation.
However, the relative amounts of N-terminally truncated Aβ in mouse models and
human AD differ considerably as their levels are much lower in mice (Rüfenacht et al.,
2005; Schieb et al., 2011). For instance, in aged Tg2576 mice, Kawarabayashi et al. (2001)
reported that only 5 % of the deposited (insoluble) Aβ is N-terminally ragged whereas
the relative abundance of N-truncated Aβ in human AD brain is approximately 70-85
%. It was further suggested that the lower percentage of N-truncated Aβ in murine
models is connected to the strikingly different solubility observed for amyloid plaques
from AD and murine brains (Kalback et al., 2002).
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1.9 treatment of alzheimer´s disease
Although there are drugs to treat the symptoms of AD, there is currently no cure. The
availabe medication targets the cholinergic system or glutamate-mediated excitotoxicity
in the brain and has been shown to have moderate effects, but does not prevent the
progression of the clinical symptoms (Bullock and Dengiz, 2005; Bullock et al., 2005;
Rogers et al., 1998; Wallin et al., 2011).
The modified amyloid cascade hypothesis suggests that modulating the production or
improving the clearance of Aβ could be promising for therapy. Thus, the idea of in-
hibitors or modulators targeting enzymes that are involved in amyloidogenic cleavage
of APP (see 1.5.1, page 13) was followed by several studies. However, this approach
has some major flaws: It has not been achieved to date to develop γ-secretase inhib-
itors that are specific for the substrates but non-toxic. β-secretase inihibitors are at a
very early developmental stage. Thus, the focus of research is currently on active and
passive immunization approaches (Lannfelt et al. (2014).
1.9.1 Active Immunization
Schenk et al. (1999) have demonstrated that active immunization against Aβ can pre-
vent plaque deposition in the PDAPP mouse model. Similar approaches were able to
support these results and even show a rescue of behavioral symptoms in transgenic
mice (Dodart et al., 2002; Janus et al., 2000; Kotilinek et al., 2002; Morgan et al., 2000).
These remarkable effects led to the initiation of clinical trials of active immunization
with Aβ preparations in AD patients. In the first clinical phase I safety study, about
60 patients were treated. Although several individuals failed to develop detectable an-
tibody titers, no adverse events were observed (Schenk, 2002). However, clinical phase
2a trials were halted due to the observation that a subset of patients developed symp-
toms of CNS inflammation and the fact that some even died from pulmonary embolism
afterwards (Ferrer et al., 2004; Nicoll et al., 2003).
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It was concluded that active immunization led to an autoimmune response, thereby
causing severe side effects (Orgogozo et al., 2003). Although a more complete follow-up
of these studies suggested slight beneficial effects in a fraction of patients later, many
researchers shifted their interest towards passive immunization strategies (Hock et al.,
2002).
1.9.2 Passive Immunization
Antibodies against Aβ are widely employed as research tools. Monoclonal antibodies
have been raised to engage with various epitopes within the Aβ sequence. Besides
their potential for detection of Aβ in, or purification of, Aβ from biological samples,
several antibodies with specific properties have been proposed for passive immuniza-
tion. Antibodies evaluated positively in preclinical trials were then humanized to avoid
species-specific immune-responses in human patients. The humanized antibodies used
in clinical trials recognize N-terminal, C-terminal or central epitopes within the Aβ
sequence or neo-epitopes of aggregated Aβ, soluble oligomers, protofibrils, plaques or
a subset of them.
Passive immunization strategies against Aβ have been successfully tested in murine
models during the past years. These studies demonstrated the capability of peripherally
administered antibodies to successfully clear Aβ from murine brain (Bard et al., 2000;
DeMattos et al., 2001; Frost et al., 2012; Wilcock et al., 2003, 2004b,c, 2006). However, it
was found that passive immunization can also cause side effects, e.g. microhemorhages
(DeMattos et al., 2012; Pfeifer et al., 2002; Racke et al., 2005; Schroeter et al., 2008; Wil-
cock et al., 2004c, 2006). Subsequently it was proposed that these side effects are in-
duced by the effector function of the antibody on microglial activation: It was shown
that reducing the effector function, for instance by de-glycosylation of the antibody, can
be one way of addressing this issue (Karlnoski et al., 2008; Wilcock et al., 2006).
The clinical trials beyond phase I mostly employed humanized monoclonal antibod-
ies against various Aβ epitopes and neo-epitopes. Some of them have been terminated
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due to lack of efficiency or adverse side effects and the overall outcomes are much less
promising than preclinical studies have suggested (Lannfelt et al., 2014).
The humanized antibody bapineuzumab (Janssen Alzheimer Immunotherapy and
Pfizer) targets fibrillar forms of Aβ preferentially, recognizing the N-terminal domain
of the peptide (Miles et al., 2013). In two clinical phase III studies, some evidence of
target engagement was reported, as well as a statistically significant reduction of Tau in
the cerebrospinal fluid of patients. However, the administration of the antibody was ac-
companied by a significant number of vasogenic edema and microhemorrhages. Thus
the development of bapineuzumab was terminated (Lannfelt et al., 2014).
Solanezumab (Eli Lilly and Co), is a humanized antibody directed against soluble
monomeric Aβ, recognizing a mid-sequence epitope. Pooled data from two phase III
studies indicated a reduction in rate of conitive decline by 34 %, but without statistical
significance. The clinical trials have been extended and solanezumab is further being
tested for the prevention of familial AD (Lannfelt et al., 2014).
Other antibodies such as the conformation-specific gantenerumab (targeting amyloid
plaques), crenezumab (against monomeric and oligomeric Aβ) and BAN2401 (recog-
nizing soluble Aβ-protofibrils) are currently under clinical investigation, too (Lannfelt
et al., 2014). However, none of these antibodies have been proven to substantially in-
fluence the progression of symptoms in AD. Additionally, Watt et al. (2014) recently
raised doubts whether antibodies used in some of the clinical studies sufficiently en-
gage with the target after administration. Passive immunotherapy is still ongoing in
clinical trials and remains a promising option to develop an efficient treatment of AD.
1.9.3 Most Recent Developments
During the past years, rapid progression has been achieved in the field of AD research.
In particular, the role of soluble toxic assemblies of Aβ and some of its N-truncated iso-
forms have increasingly gained attention. It has become widely accepted that AβpE3−X
may play an important role in AD and this isoform has been shown to exhibit devi-
ant biochemical properties compared with N-terminally intact Aβ (see 1.8.3, page 24).
The interest in Aβ starting at residue 4 as another abundant N-truncated species is
27
increasing as well (Bouter et al., 2013, 2014). Most of the immunization approaches
against Aβ have been shown to have important disadvantages such as negative side
effects or a lack of efficacy in humans (see 1.9.1, page 25 and 1.9.2, page 26). These dif-
ficulties further underline the need for a more specific drug that is safe and efficacious
at the same time. Therefore, interest in N-truncated Aβ as a possible therapeutic target
has increased. Marcello et al. (2011) showed that patients with AD have reduced levels
of autoantibodies against N-truncated Aβ. A first pilot study of anti-AβpE3−X immun-
otherapy in mice had promising outcomes (Wirths et al., 2010c). During the time that
the studies described here were conducted two other studies supported the importance
of AβpE3−X as a possible target for treatment, describing altered Aβ levels after passive
immunization with anti-AβpE3−X antibodies in two different mouse models without
induction of microhemorrhage, a commonly seen side effect (DeMattos et al., 2012;
Frost et al., 2012). McLaurin et al. (2002) reported that therapeutic benefits observed in
mice after active immunization with protofibrillar Aβ are due to antibodies recogniz-
ing residues 4-10 of the Aβ sequence. However, the question if and how Aβ4−X can be
employed for therapeutic strategies remains unanswered.
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1.10 aims of the study
Among others, the group of Prof. T.A. Bayer (Göttingen) has developed several mono-
clonal antibodies specifically targeting N-terminally truncated Aβ with different bind-
ing preferences that could have therapeutic potential: NT4X-167 was raised against an
Aβ4−X epitope; 1-57 is a non-conformation-specific antibody against AβpE3−X (Wirths
et al., 2010a) and 9D5 is an oligomer-specific antibody against AβpE3−X (Wirths et al.,
2010c). The experimental work carried out in this doctoral thesis aims to extend and
broaden the investigations of N-terminally truncated Aβ as a possible target for AD
therapy. To this end, a comparative pilot study with three monoclonal antibodies
(NT4X-167, 1-57, 9D5) engaging with different fractions of N-truncated Aβ was de-
signed. This comparative approach aims to give insight into the contribution of the
two major fractions of N-terminally truncated peptide isoforms, AβpE3−X and Aβ4−X.
Since discrepancies regarding the abundance of N-terminally truncated Aβ between
murine models and human AD have been described (see 1.8.3, page 24), it was of
particular importance to thoroughly investigate the model that should be employed
(5XFAD) regarding its suitability for the purpose of the study. A homozygous 5XFAD
strain was created to elevate transgene expression and Aβ production. This was in-
tended to improve detection and analysis of the less abundant N-truncated peptide
species. The aims of the study can be summarized in main objectives/main questions
as follows:
• Characterization of the newly developed monoclonal antibody NT4X-167
• Generation and Characterization of a homozygous 5XFAD strain
• Is the 5XFAD model suitabe to study the effects of N-terminally truncated Aβ?
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2.1 material
2.1.1 Chemicals, Reagents, Kits and Technical Devices
The chemicals used within this study are listed in table 2.1, reagents and formulations
used are listed in table 2.2. Kits used are listed in table 2.3 and the technical devices
used are listed in table 2.4.
2.1.2 Antibodies
The primary antibodies used for Western Blot and/or Immunohistochemistry are lis-
ted in Table 2.5. Secondary antibodies employed in western blotting or immuno-





4´6-Diamidin-2-Phenylindol Roth, Karlsruhe, Germany
Acetonitrile Merck, Darmstadt, Germany
Agarose Lonza, Basel, Switzerland
Ammoniumbicarbonate Sigma, St. Louis, MO, USA
Boric Acid Sigma, St. Louis, MO, USA
Bovine serum albumin Roth, Karlsruhe, Germany
Citric Acid Roth, Karlsruhe, Germany
Molecular Grade Water Braun, Melsungen, Germany
Diaminobenzidin Roth, Karlsruhe, Germany
Ethylenediaminetetraacetic Acid Roth, Karlsruhe, Germany
Ethanol Merck, Darmstadt, Germany
Ethidiumbromide Roth, Karlsruhe, Germany
Formic Acid 98 % Roth, Karlsruhe, Germany
Hydrochloric Acid Merck, Darmstadt, Germany
Hydrogenperoxide Roth, Karlsruhe, Germany
Isopropanole Roth, Karlsruhe, Germany
Liquid Nitrogen Air Liquide
Methanol Roth, Karlsruhe, Germany
Sodium Chloride (NaCl) Roth, Karlsruhe, Germany
Sodium dodecyl sulfate Roth, Karlsruhe, Germany
Sodium hydrogen phosphate Merck, Darmstadt, Germany
Sodium hydroxide AppliChem
Sinapinic Acid Bruker Daltonics
Thioflavin S Sigma, St. Louis, MO, USA
Tris(hydroxymethyl)-
aminomethane Roth, Karlsruhe, Germany
Triton X-100 Roth, Karlsruhe, Germany
Tween-20 Roth, Karlsruhe, Germany





10X Reaction Buffer for PCR Axon, Kaiserslautern, Germany
100 bp Ladder Bioron, Ludwigshafen, Germany
Agarose Sample Buffer (Blue Juice) Life Technologies, Carlsbad, CA, USA
Amyloid-beta Peptides, Synthetic Peptide Specialty Laboratories, Heidelberg,Germany
Cømplete Proteinase Inhibitor
tablets Roche, Basel, Switzerland
Taq DNA-Polymerase Axon, Kaiserslautern, Germany
Desoxyribonukleoside-
triphosphates Axon, Kaiserslautern, Germany
Dynabeads M-280 sheep
anti-mouse Life Technologies, Stockholm, Sweden
Dynabeads M-280 sheep anti-rabbit Life Technologies, Stockholm, Sweden
Fetal Cow Serum Thermo Fisher Scientific, Waltham, MA, USA
Fluorescence Mounting Medium DAKO, Glostrup, Danmark
Hematoxylin Solution Roth, Karlsruhe, Germany
Ketamine 10 % Medistar, Ascheberg, Germany
Luminata crescendo Western HRP
Substrate Merck, Darmstadt, Germany
Magnesium chloride (MgCl2) for
PCR Axon, Kaiserslautern, Germany
Native Anode Buffer for BN/CN SERVA, Heidelberg, Germany
Native Kathode Buffer for BN/CN SERVA, Heidelberg, Germany
Native Marker, Liquid Mix for
BN/CN SERVA, Heidelberg, Germany
Nitrocellulose Membranes,
Hyobond ECL GE Healthcare, Chalfont St. Giles, GB





Paraffin for Tissue Embedding Roth, Karlsruhe, Germany
PBS pH 7.4 Sigma, St. Louis, MO, USA
PBS pH 7.4 Merck, Darmstadt, Germany
4-16% ServaGelTM N 4-16 SERVA, Heidelberg, Germany
Primers for genotyping Eurofins, Ebersberg, Germany
Proteinase K Peqlab, Erlangen, Germany
Roti-Histokitt Roth, Karlsruhe, Germany
Sample Buffer for Blue Native (2x) SERVA, Heidelberg, Germany
SERVA Blue G Solution for Blue
Native, 1 % SERVA, Heidelberg, Germany
Superfrost glass slides Thermo Fisher Scientific, Waltham, MA, USA




DC Protein Assay Kit Biorad Laboratories, Hercules, CA, USA
DyNAmo Flash SYBR Green qPCR
Kit Thermo Fisher Scientific, Waltham, MA, USA
RotiQuant Protein Assay Roth, Karlsruhe, Germany





Biophotometer Eppendorf, Hamburg, Germany
Centrifuge (Stratos Biofuge
Heraeus) Thermo Fisher Scientific, Waltham, MA, USA
EG1140 H Embedding Station Leica, Wetzlar, Germany
Electrophoresis Chamber
BlueVertical PRiME Serva, Heidelberg, Germany
Embedding Casettes Simport, Beloeil, QC, Canada
Eppendorf LoBind reaction tubes Eppendorf, Hamburg, Germany
Heating block (UNO-Thermoblock) Biometra, Göttingen, Germany
HM 335E Microtome Thermo Fisher Scientific, Waltham, MA, USA
Individually Ventilated Cages Tecniplast, Hohenpleissberg, Germany
Odyssey FC Li-Cor, Bad Homburg, Germany
BX-51 Microscope Olympus, Shinjuku, Japan
0.2 ml PCR Tubes Greiner Bio-One, Kremsmuenster, Austria
Semi-Dry Blotting Chamber Biorad Laboratories, Hercules, CA, USA
Lab Cycler for PCR SensoQuest, Göttingen, Germany
Savant SPD131DDA Speed Vac
Concentrator Thermo Fisher Scientific, Waltham, MA, USA
Nutating Shaker Gesellschaft für Labortechnik (GFL), Burgwedel,Germany
MX3000P Real-Time Cycler Stratagene, Santa Clara, CA, USA
Pap Pen Lipid Pen Kisker Biotech, Steinfurt, Germany
Ultraflextreme Mass Spectrometer Bruker Daltonics, Billerica, MA, USA
Uvette 220-1600 nm Cuvettes Eppendorf, Hamburg, Germany
Sonics Vibra-Cell VCX-130 Sonifier
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Sonics & Materials, Newtown, USA
ThermoMixer compact Eppendorf, Hamburg, Germany
TP 1020 Automatic Tissue
Processor Leica, Wetzlar, Germany
Vortexer, Vortex Genie 2 Scientific Industries, Bohemia, NY, USA
Water Bath for mounting of
paraffin tissue Medax, Olching, Germany





1-57 Synaptic Systems, Göttingen, Germany Wirthset al. (2010a)
24311 Bouter et al. (2013)
4G8 Covance, Princeton, NJ, USA
6E10 Covance, Princeton, NJ, USA
82E1 Immuno-Biological Laboratories, Minneapolis,MN, USA
9D5 Synaptic Systems, Göttingen, Germany Wirthset al. (2010a)
Abeta42 Synaptic Systems, Göttingen, Germany
G2-10 Merck Millipore, Darmstadt, Germany
IC16 Gift of Prof. Dr. Sascha Weggen, Heinrich-HeineUniversity Düsseldorf, Germany




Goat-anti-rabbit HRP conjugated Dianova, Hamburg, Germany
Rabbit-anti-mouse HRP-conjugated Dianova, Hamburg, Germany
Rabbit-anti-mouse IgG biotinylated DAKO, Glostrup, Danmark
Swine-anti-rabbit IgG biotinylated DAKO, Glostrup, Danmark
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2.2 biochemical methods
2.2.1 Electrophoresis and Western Blotting of Synthetic Peptides
Synthetic Aβ peptides were dissolved at 1 mg/ml in 10 mM Sodium hydroxide (NaOH)
and sonicated for 5 minutes in an ice-cold sonication water bath. Aliquots of 10 µl were
flash frozen in liquid nitrogen and stored at -80 °C prior to use. 2 µg peptide per well
(mixed with an equal volume of sample buffer for blue native (2x)) were loaded on
Vertical Native Gels and run at a constant current of 120 V in the BlueVertical PRiME
electrophoresis chamber containing Native Kathode Buffer for BN/CN supplemented
with SERVA Blue G Solution for Blue Native, 1 % and Native Anode Buffer for BN/CN.
After electrophoresis, the peptides were transferred onto 0.45 µm nitrocellulose mem-
branes for 30 minutes per membrane at constant 25 mA in a semi-dry transfer chamber.
Free binding sites were blocked with 4 % (w/v) non-fat dry milk dissolved in Tris-
buffered saline supplemented with Tween-20 (TBS-T) (50 mM Tris(hydroxymethyl)-
aminomethane (Tris) pH 8.0 supplemented with 0.05 % (v/v) Tween-20) for one hour
at acRT. For detection, the primary antibodies NT4X-167 (0.5 µg/ml), 1-57 (0.5 µg/ml),
IC16 (0.25 µg/ml) and 24311 (0.5 µg/ml) were dissolved in TBS-T and incubated on
a shaker over night at 4 °C. After three washing steps (5 minutes each) with TBS-T,
secondary antibodies rabbit-anti-mouse HRP-conjugated or goat-anti-rabbit HRP con-
jugated were diluted 10000-fold in TBS-T and incubated with the membrane for 2 hours
at Room Temperature (RT). Exposure was facilitated with 1 ml of Luminata crescendo
Western HRP Substrate in an Odyssey Fc.
2.2.2 Immunohistochemistry on Paraffin Sections
Mouse tissue samples were prepared and processed similar to the way described
previously (Wirths et al., 2001). Paraffin sections of 4 µm mounted on superfrost slides
were de-parrafinized in two steps (5 minutes each) by the use of 100 % Xylene. Then,
sections were re-hydrated in aqueous ethanol solutions with descending ethanol con-
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centrations (100 % ethanol for 10 minutes, 95 % (v/v) for 5 minutes, 70 % for 5 minutes)
and subsequently immersed for 5 minutes in deionized water. In the next step, sections
then were pretreated with 0.3 % (v/v) H2O2 in Phosphate-buffered saline (PBS) for
blocking of endogenous peroxidases and then washed for 5 minutes in deionized wa-
ter. For antigene retrieval, the tissue was treated with citrate buffer (0.01 M citric acid,
pH adjusted to 6.0 with NaOH) at 95 °C and washed again in PBS for 5 minutes. A
second antigene retrieval step of a 3-minute incubation in 88 % (v/v) formic acid was
performed and the slides were washed again twice in PBS. In sections treated this way,
unspecific binding sites were blocked for 1 hour at RT in blocking solution (PBS sup-
plemented with 10 % (v/v) fetal cow serum and 4 % (w/v) fat free milk powder). The
slices were indivdually circled with a Lipid Pen and primary antibodies were applied
in PBS supplemented with 10 % (v/v) fetal cow serum for 16 hours at RT. The slides
were washed in PBS supplemented with 0.5 % (v/v) Triton X-100. This was followed by
incubation (1 hour at 37 °C) with biotinylated secondary antibody rabbit-anti-mouse
or swine-anti-rabbit in PBS supplemented with 10 % (v/v) fetal cow serum, before
staining was visualized using the ABC method (Vectastain ABC kit). To this end, a
1:100 dilution of both Solution A and B in PBS supplemented with 10 % (v/v) fetal
cow serum was prepared and incubated with the slices for 30-60 minutes at 37 °C.
Visualization was then facilitated after 15 minutes washing in PBS by exposure of the
slices to 25 µg/ml diaminobenzidin and 0.0025 % (v/v) H2O2 dissolved in an aqueous
solution of 50 mM Tris pH 7.4. The sections were washed twice in PBS for 5 minutes
and, except for the case of immunohistochemistry for plaque load quantification, coun-
terstained in hematoxylin solution for 45 seconds. After washing in deionized water
for five minutes under constant exchange (running tab), sections were de-hydrated in
a reversed aqueous ethanolic solution chain (as for re-hydration, see above), followed
by two five-minutes steps of washing in xylene. The so treated sections were then
embedded with Roti-Histokitt and left to dry for at least 48 hours prior to examina-
tion. Primary antibodies used were: Mouse monoclonal antibodies NT4X-167 reacting
with AβpE3−X and Aβ4−X (1 µg/ml, visualization in diaminobenzidine solution for 4
minutes), 1-57 reacting with AβpE3−X (1 µg/ml, visualization for 1 minute), G2-10 re-
acting with AβX−40 (3 µg/ml, visualization for 3 minutes), 82E1 reacting with Aβ1−X
40
(1µg/ml, visualization for 1 minute), and rabbit polyclonal antibody Abeta42 reacting
with AβX−42 (0.5 µg/ml, visualization for 30 seconds) as well as 24311 (0.5 µg/µl,
visualization for 2 minutes).
2.2.3 Thioflavin S Staining of Paraffin Sections
For Thioflavin S fluorescent staining as in Christensen (2009), paraffin tissue was de-
paraffinized and rehydrated as in 2.2.2, washed twice (1 minute) in deionized wa-
ter and then treated with 1 % (w/v) ThioflavinS in aqueous solution for 8 minutes.
Sections were washed twice again for 1 minute in water and immersed in the Thio-
flavin S solution for another 4minute, washed twice in 80% (v/v) ethanol and three
times in water (1minute each), counterstained in a 1 % (w/v) aqueous solution of
4´6-diamidin-2-phenylindol, washed again in water for five minutes and embedded in
Aqueous Fluorescent Mounting Medium.
2.2.4 Lysis of Murine Brain Tissue
Brains were homogenized in 8-fold amount of Tris-buffered saline (TBS) Lysis Buffer
(50 mM Tris, pH 8.0 supplemented with 1 tablet/10 ml of Cømplete Protease Inhibitor
cocktail (Roche)) and homogenates were spun down for 20 minutes at 17.000 x g, 4 °C
in a stratos Biofuge. Supernatant (termed TBS fraction) was separated. The pellet was
resuspended in 1 ml TBS lysis buffer and spun down again. The supernatant was dis-
carded and the pellet dissolved in Sodium dodecyl sulfate (SDS) lysis buffer (2 % SDS,
supplemented with 1tablet/10ml Cømplete Protease inhibitor cocktail) using the Vibra-
Cell sonifier 150 at power ‘2‘ with 10 single pulses. The lysate was spun down again
as described above and the supernatant (termed SDS-Fraction) was separated. Total
protein concentrations of both fractions were determined using the RotiQuant Protein
Assay with Bovine serum albumin (BSA) as a standard.
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2.2.5 Isolation of Genomic DNA and Genotyping of Animals
Genomic DNA was isolated from tail biopsies. Per sample, 500 µl of lysis buffer
(100 mM Tris/hydrochloric acid pH 8.5, 5 mM ethylenediaminetetraacetic acid, 0.2 %
(w/v) SDS, 200 mM NaCl, 10 µl/ml proteinase K) were added and left overnight at
55 °C in a Thermomixer Compact under gentle agitation. Solutions were centrifuged
at 13000 rpm in the stratos centrifuge for a duration of 10 minutes and the pellet was
discarded. The lysates were diluted into 500 µl of isopropanole. Samples were then
vortexed and centrifuged again for 10 minutes at 13000 rpm. Pellets were washed in
500 µl of 70 % (v/v) ice-cold ethanol and spun down for 10 minutes at 13000 rpm.
After the supernatant was discarded, the pellets were left do dry at RT and further
dissolved in 50 µl H2O. The DNA concentration was then measured using the Bio-
photometer (DNA preparations with A260/A230 and A260/A280 ratios > 1.8 were
considered sufficiently pure) and diluted in molecular grade water to reach a concen-
tration of 20 ng/µl. 5XFAD mice carrying the transgene were identified using conven-
tional Polymerase-chain-reaction (PCR) as follows:
A reaction mix for the polymerase chain reaction was set up according to table 2.7
without the DNA. DNA was then given into a PCR reaction tube and the prepared
reaction mix (18 µl) was added. The cycling protocol is listed in table 2.8. After this,
the samples were subjected to agarose gel electrophoresis to identify transgene animals.
100 ml of TBE buffer (89 mM Tris, 89 mM boric acid, 2 mM ethylenediaminetetraacetic
acid) were added to 2 g agarose and heated in a microwave until the agarose was com-
pletely dissolved. 3 µl ethidumbromide (10 mg/ml) were added and the gel was casted
in a casting tray with a comb to form wells. After the gel was cooled down, the comb
was removed and the samples (10 µl mixed with 1 µl of 10X agarose sample buffer)
were loaded into the wells. The gel was run in a horizontal electrophoresis chamber
(Biorad Laboratories, Hercules, CA, USA).For size indication, one well was filled with
5 µl of 100 bp DNA ladder and run in TBE buffer for approximately 45 minutes at 120
V constant current. The DNA in the gel was visualized under a UV lamp. Animals that




Master Mix for 5XFAD Genotyping
Reagent Volume [µl]
DNA (20 ng/µl) 2.0
Primer hAPP-for (table 2.9) 0.5
Primer hAPP-rev (table 2.9) 0.5
dNTPs (2 mM) 2
MgCl2 (25 mM) 3.2
10X reaction buffer 2
Molecular grade water 9.6
Taq polymerase (5 U/ul) 0.2
Table 2.8
Cycling Programm for 5XFAD Genotyping





5 Repetition of steps 2 - 4 (35 times)
6 72 300
7 4 for storage
2.2.6 Quantitative Real-Time PCR Genotyping
To identify homozygous animals, quantitative Real-Time PCR was performed using
a Stratagene MX3000P Real-Time Cycler with 10 ng of genomic DNA per reaction.
For quantification of the PCR product, the SYBR-green based DyNAmo Flash SYBR
Green qPCR Kit containing ROX as an internal reference dye was used, adopting the
conventional APP genotyping protocol for 5XFAD mice. The reaction mix and cycling
protocol are given in tables 2.10 and 2.11. The reaction was performed in duplicates
and separate tubes for each pair of primers.
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Table 2.9
Primer used for genoyping of 5XFAD mice
Primer Sequence
hAPP-for 5´ - GTA GCA GAG GAG GAA GAA GTG - 3´
hAPP-rev 5´ - CAT GAC CTG GGA CAT TCT C – 3´
mAPP-for 5´- TCT TGT CTT TCT CGC CAC TGG C – 3´
mAPP-rev 5´ - GCA GTC AGA AGT TCC TAG G – 3´
Table 2.10
Reaction Mix for 5XFAD Quantitative Real-Time Genotyping
Reagent Volume [µl]
DNA (20 ng/µl) 2.0
Primer mAPP-for or hAPP-for
(table 2.9) 0.5




Molecular grade water 6.3
Average CT values were determined from the duplicates, and relative quantification
was performed using murine APP as a reference gene for normalization. The transgene
levels of human APP were normalized to those of murine APP and calibrated to a
selected heterozygous 5XFAD animal using the ∆∆CT method (Schmittgen and Livak,
2008) (i):
(i) AmountGene = 2−∆∆CT
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Table 2.11
Cycling Programm for 5XFAD Quantitative Real-Time Genotyping









9 4 for storage
For an animal (q), the level of human APP (hAPP) gene expression normalized to the
expression of murine APP (mAPP) as a reference gene and calibrated to a confirmed
hemizygous animal (cb), ∆∆CT is calculated as follows (ii) and (iii):
(ii) ∆CT = CT ,hAPP - CT ,mAPP
(iii) - ∆∆CT = −T ,q −∆CT ,cb
Figure 2.1 gives a typical example, with animals A and C being identified as poten-
tially homozygous 5XFAD (5XFADhom) animals.
2.2.7 Immuno-precipitation of Amyloid-beta
Frozen murine brain samples (three left hemibrains from 7-month-old hemizygous
5XFAD mice) were homogenized to powder in liquid nitrogen using mortar and pistil
and aliquoted at 50 mg in 1.5 ml Eppendorf LoBind reaction tubes (LoBind tubes were
used for all subsequent steps). One aliquot of brain powder was dissolved in 330 µl
0.01 M PBS and sonicated with the Sonics Vibra-Cell VCX-130 sonifier for one minute
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Figure 2.1
A typical example for Real-Time-PCR genoyping of 5XFAD mice. Here the animals A and C
whose human APP gene dose was appromately twice as high in comparison to a confirmed
hemizygous animal (D) were identified as potential homozygous 5XFAD. Animals B and E
were considered hemizygous.
applying pulses of 2 s at an amplitude of 30 %. Formic acid was added to a final
concentration of 70 % (v/v) and the sample was sonicated again, the insoluble frac-
tion spun down for 20 minutes at 17.000 g. The pellet was discarded and concentra-
tions were determined using a DC Protein Assay Kit, based on the modified Lowry
method with BSA as standard (Lowry et al., 1951). The extract was aliquoted at 200 µl
and finally dried down in the SpeedVac at 45 °C and stored at –80 °C. For Immuno-
Precipitation (IP), the extract was re-dissolved in 100 % FA to a concentration of 4 mg
total protein/ml and neutralized diluting it by 21-fold (50 µl sample + 1100 l of 1 M
Tris, 0.5 M Na2HPO4). For IP of Aβ from murine brain lysates, a 1:1 mixture of the
antibodies 6E10 (Epitope 4–9) and 4G8 (Epitope 17–24) was used. Paramagnetic Dyna-
beads M-280 sheep-anti-mouse/rabbit were concentrated using a magnetic rack and
washed twice in 1 ml PBS supplemented with 0.1 % (w/v) BSA and coupled with the
capture antibody mixture (8µg/50 µl bead suspension) over night under gentle agita-
tion. After coupling, beads were washed three times in PBS/BSA and incubated with 1
ml of neutralized sample for 6 hours. Following incubation, beads were washed twice
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with PBS/BSA and twice with 50 mM ammoniumbicarbonate and eventually eluation
was facilitated using 100 µl 0.5 % (v/v) FA. After transfer to a new LoBind vial, the
eluate was dried down at 45 °C in the SpeedVac and stored at -80 °C prior to use.
2.2.8 MALDI-TOF detection of Amyloid-beta
For Matrix-Assisted Laser Desoption/Ionisation - Time of Flight (MALDI-TOF), the
dried eluate obtained from IP was re-dissolved in 20 µl of 20 % (v/v) acetonitrile,
0.1 % (v/v) formic acid and sonicated in the water bath for 10 minutes. Sample was
plated at 1-2 µl + equal volume of sinapinic acid as matrix (20 mg/ml in a 1/1 (v/v)
mixture of acetonitrile/water). For MALDI-TOF, samples were re-dissolved in 20 µl of
20 % (v/v) acetonitrile with 0.1 % (v/v) FA, sonicated in the ultrasound waterbath for
10 minutes, spun down briefly and subjected to the steel target plate at 1 µl. Matrix
solution was added in equal amounts directly onto the target and the mixture was
allowed to crystallize at room temperature until found dry. Desorption and time-of-
flight mass spectrometry was carried out in a Ultraflextreme mass spectrometer in
reflection mode at a laser intensity of 80-90 % collecting accumulated spectra of a total
number of 10000 single laser shots. For calibration, 1 µl of a synthetic Aβ peptides
mixture (AβpE3−40/42 and Aβ4−40/42, 0.01 mg/ml each in 10 mM NaOH) was plated
with an equal amount of matrix. Baseline was substracted from the obtained spectra.
2.3 animals and animal experiments
2.3.1 General Considerations
All animals used in this study were of the species Mus musculus. All animals used for
these studies were housed under specific pathogen-free (SPF) conditions in individu-
ally ventilated cages at the central animal facility of the Göttingen University Medical
Center. Mice were kept with a constant 12 h/12 h inverted dark/light daily cycle (light
from 8.00 p.m. to 8.00 a.m.) and had ad libitum-access to food and water.
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All experimental procedures were performed during the night cycle (8.00 a.m. to 8.00 p.m.)
Mice were handled according to the guidelines of the ’Society for Laboratory Animals
Science’ (GV-SOLAS) and the guidelines of the ’Federation of European Laboratory
Animal Science Association’ (FELASA). All animal experiments were approved by the
"Landesamt für Verbraucherschutz und Lebensmittelsicherheit" (LAVES) Niedersach-
sen. Individuals that displayed conditions such as blind eyes or massive loss of weight
( > 20 %) at any time before or during the experiments were sacrificed immediately
and excluded from all analyses.
2.3.2 Transgenic Mice
In this work, the 5XFAD model, initially described by Oakley et al. (2006) has been
used (see also 1.8.2, page 22). Mice were maintained on a C57Bl6/J genetic background
(Jackson Laboratories, Bar-Harbor, ME, USA) (Jawhar et al., 2012).
2.3.3 Tissue Collection and Preservation
Mice were deeply anesthetized by intraperitoneal injection with a mixture of ketam-
ine (100 mg/kg) and xylazine (10 mg/kg) and transcardially perfused with ice-cold
PBS. Brains and spinal cords were dissected, spinal cords and right brain hemispheres
including olfactory bulb and cerebellum were placed into embedding casettes and post-
fixed in phosphate-buffered formaldehyde solution Roti Histofix for five to seven days.
The tissue was treated according to Wirths et al. (2010a): Using a TP 1020 Automatic
Tissue Processor, the tissue was first submerged in Histofix for 5 minutes and the
carried over to deionized water (30 minutes), dehydrated with aqueous solutions of
ascending ethanol content (50 % (v/v), 60 %, 70 %, 80 %, 90 % for one hour each) fol-
lowed by two times xylene (one hour each), and further two steps in melted paraffin
(one hour each) and finally embedded in paraffin. Spinal cords and left hemispheres
(olfactory bulb and cerebellum removed) were flash frozen on dry ice and stored at
-80 °C prior to use. Paraffin-embedded tissue was sliced to 4 µm sections with a
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microtome, mounted on superfrost slides in a water bath at RT and further fixed on
the slides in a second water bath at approximately 52 °C. Before using the sections for
immunohistochemistry, the slices were dried over night at 37 °C.
2.3.4 Passive Immunization of 5XFAD Mice
All monoclonal antibodies used for passive immunization consisted of a murine IgG2b
backbone: NT4X-167, 1-57, 9D5 dissolved in PBS (c = 1 mg/ml) were obtained from
Synaptic Systems, Göttingen (Germany), aliquoted, flash frozen in liquid nitrogen and
thawed at RT right before injection.
Female hemizygous 5XFAD (5XFADhem) mice were immunized in a chronic par-
enteral approach; animal received weekly intraperitoneal injections, over a course of
ten weeks, starting at the age of 4.5 months. The dosage of antibodies was 10 mg/kg
body weight. Two days after the 9th administration, the mice were subjected to behavi-
oral testing, starting with the cross maze test (see 2.3.6, page 52) at day one followed
by the elevated plus maze (see 2.3.6, page 51). After a one-day pause, morris water
maze training started (see 2.3.6, page 53). The last treatment was administered ap-




The clasping phenotype of mice was performed as determined as previously described
in Miller et al. (2008). Mice were suspended by the tail and given a score from 0-3,
with 0 representing no clasping, 1 for forepaw clasping only, 2 for forepaws and one
hindpaw clasping, and 3 for all paws clasping.
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Balance Beam Task
The balance beam test (Hau and Schapiro, 2002; Luong et al., 2011) was performed
as follows: A 50 cm long wooden round beam (1 cm in diameter) with a 9 x 15 cm
escape platform at either end was used to assess balance and general motor function.
The beam was elevated by 40 centimeters and the ground below was padded to prevent
mice from injury. Mice were gently released in the middle of the beam and given 60 s to
escape to one of the platform. Time on the beam was recorded as latency to fall. Escape
to one of the platforms was recorded as full time (Jawhar et al., 2012). For statistics,
the average of three trials per mouse, with an interval of at least 20 minutes between
the trials was analyzed. Between the single trials, the apparatus was cleaned with 70 %
ethanol to remove any olfactory cues and marks left by the animals during testing.
String Suspension Task
The string suspension task allows to assess animals for motor coordination and grip
strength (Arendash et al., 2001b; Hullmann, 2012). Similar to the balance beam, animals
were placed on a string connecting two escape platforms of 9 x 15 cm. String and
platforms were approximately 40 cm above the padded ground. The performance was
rated according to the following system: 0 = unable to remain on string; 1 = mouse
hangs on platform by paws only; 2 = as 2, but with attempts to climb up; 3 = mouse
sits on the string and keeps balance; 4 = mouse is able to move laterally on the string;
5 = escape to one of the platforms (Jawhar et al., 2012; Moran et al., 1995). For analysis,
the average ranking out of three independent trials (60 s each) per mouse was taken.
Between the single trials, the apparatus was cleaned with 70 % ethanol to remove any
olfactory cues and marks left by the animals during testing.
2.3.6 Behavioral Testing
Elevated Plus Maze
This paradigm based on the tendency of a mouse to avoid open spaces was originally
described in Karl et al. (2003). The mice were introduced into an elevated, cross-shaped
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Figure 2.2
Behavioral testing paradigms. A Elevated plus maze B Cross Maze C Morris water maze.
Reprinted with kind permission of Dr. Anika Saul, Göttingen
apparatus (length 15 cm x width 5 cm) with two enclosed arms opposing each other
and two opposing wall-free arms (See Figure 2.2). The apparatus was elevated by 75 cm
above ground level. Mice were allowed to freely explore the apparatus for 5 minutes.
For analysis, the percentage of time spent in the open/closed arms was displayed.
The total distance travelled and average speed in the mice were measured as control
parameters to judge the locomotion abilities of the mice. Between the single trials, the
apparatus was cleaned with 70 % ethanol to remove any olfactory cues and marks left
by the animals during testing.
Cross Maze
The cross maze task was performed similar to the way described in Jawhar et al. (2012).
In brief, the mice were subjected to a cross-shaped symmetrical maze with 4 arms
(length 30 cm x width 8 cm x height 15 cm) (See Figure 2.2). To start the test, mice
were placed in the center area of the apparatus and allowed to freely explore the setup
for 10 minutes. Sequential visits of all four arms (e.g. arm 1, arm 3, arm 2, arm 4) were
counted as correct alternations, with overlap of sequences being allowed (Arendash
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et al., 2001b). The percentage of alternations was expressed in regard to the number
of total possible alternations (n(arm antries)-3). Total distance travelled and average
speed in the maze were measured as control parameters. This test is based on the
natural tendency of mice to explore the least visited arm rather than a recently visited
one (Wietrzych et al., 2005). Between the single trials, the apparatus was cleaned with
70 % ethanol to remove any olfactory cues and marks left by the animals during testing.
Morris Water Maze
The morris water maze paradigm (originally described in Morris (1984)) was per-
formed as follows, similar to the way described in Bouter et al. (2013). The apparatus
consisted of a round steel pool with a diameter of 120 cm filled with water (made
opaque by adding non-toxic white paint) up to approximately 20 cm and virtually
divided into four quadrants (see Figure 2.2). For acclimatization and testing of motor-
ic/visual abilities, an animal was released at the border of the pool and trained over
three days (cued training stage) to find a visible (cued) platform (15 cm in diameter)
slightly reaching over the water level. A blue plastic cylinder (5 cm in diameter) with
white vertical stripes served as the platform cue. Each training day consisted of four
independent trials. Between trials, the platform position and release point were semi-
randomly shifted between four different positions excluding the quadrant being the
target quadrant in later stages (Vorhees and Williams, 2006). The duration of a single
trial was 60 s. In case a mouse did not find the platform, it was gently directed to
reach the platform and allowed to rest for five seconds. No external cues were used
during the cued training stage. Having finished the cued training stage, water was
filled up to a level of 0.5 cm above the platform, the platform cue was removed and
proximal/distal cues placed at the pool borders in the middle of each virtual quadrant.
Mice were then trained during a five-day period (acquisition training stage) with four
trials a day to localize the hidden platform in the target quadrant. Again, mice were
released from four different positions at the pool border, allowed to freely search for
the platform for 60 s and given five seconds to rest on the platform. Mice that did
not localize the platform within the given time were again gently directed towards the
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platform and allowed to familiarize. At all stages, the animals were allowed to rest and
dry between two trials for at least 15 min. After the acquisition training stage, the mice
were subjected to a single probe test trial where the platform was removed and the
mice were allowed to search freely for 30 s. Parameters taken into analysis were aver-
age swimming speed and time to reach the platform position (escape latency) for the
cued and acquisition training stages. For the probe trial, swimming speed was meas-
ured as a control parameter and further, the percentage of time in the four quadrants
as well as the average proximity to the memorized target platform position was calcu-
lated. Between the single trials, the apparatus was cleaned with 70 % ethanol to remove
any olfactory cues and marks left by the animals during testing.
2.4 computational methods
2.4.1 Quantification of Plaque Load
Extracellular Aβ load was evaluated in sagittal brain sections of 4 µm for anterior mo-
tor cortex (stereotactic coordinates from the bregma: AP 3 – 2 mm, D 0.75 – 1.75 mm)
and thalamus (AP -1 - 2 mm,D2.25–3.25 mm). Five to six sections per mouse and per
antibody were analyzed by immunohistochemistry with diaminobenzidine as a chro-
mogene and Thioflavin S fluorescent staining. Sections starting from the lateral cutting
plane of approximately 0.36 mm from the bregma were assessed for plaque load quan-
tification, and pairs of parallel sections were stained in three independent experiments
for each animal and antibody/dye. Therefore, the sections for the three experimental
turns using the same antibody/dye were 80 µm apart from each other. Images were
taken at 100-fold magnification using an Olympus BX-51 microscope equipped with an
Olympus DP-50 camera. Using ImageJ the images (Thioflavin S images were inverted)
were binarized to 8-bit black and white images and a fixed intensity threshold was
applied defining the stained area. For the subiculum, an ellipsoid area of constant size
approaching the desired brain region was selected before quantification, and the out-
side of this ellipsoid was cleared. The single measurements (% area fraction) for each
section were normalized to the average of the PBS injected control group, giving a
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relative plaque load level expressed in percent for each individual experimental turn.
For statistical analysis, the average of the three experimental turns was used.
2.4.2 Software and Statistics
For all behavioral testing, AnyMaze Software combined with a camera (Computar,
Commack, NY, USA) for tracking was used. Statistical analysis was performed using
GraphPad PRISM 6 (GraphPad Software, San Diego, CA, USA). Quantitative Real-Time
PCR Data were collected and processed with the MxPro MX3000P Software (Strata-
gene, Santa Clara, USA). Images were processed with ImageJ V1.41, NIH, USA and/or
Adobe Photoshop CS2 (Adobe Systems, San Jose, CA, USA). Figures were composed
with Adobe Photoshop CS2 and/or Adobe Illustrator CS 2 (Adobe Systems, San Jose,
CA, USA). The mass-spectrometric data was processed with the flexAnalysis software
Version 3.0.54.0 (Bruker Daltonics, Bremen, Germany).
Statistical tests performed were students-two-tailed t-test, one-way-Analysis of Vari-
ance (ANOVA) and repeated-measures ANOVA for grouped analysis, followed by
Dunnet´s or Tukey´s post-hoc tests for mutiple comparison. Data were expressed as
mean ± SEM and a 0.5 % general significance niveau was defined, with significance
levels as follows: *: p < 0.05; **: p < 0.01; ***: p < 0.001.
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3.1 characterization of the antibody nt4x-167
Peptide-binding Properties of NT4X under Native Conditions
Freshly dissolved Aβ peptides were probed on a nitrocellulose membrane under blue
native conditions, where peptides migrate approximately proportional to their mo-
lecular weight. All peptide species tested, though freshly dissolved, formed higher
molecular weight oligomers of different sizes immediately. NT4X-167 detected both
AβpE3−40/42 and Aβ4−40/42. Interestingly, the latter migrated in a distinct band of ap-
proximately 50 kDa, though the other peptides probed were present in different distinct
bands of approximately 20, 30 and 50 kDa for AβpE3−40 and approximately 30, 50, 55
and > 70 kDa for AβpE3−42. Probing with N-terminal specific antibody IC16 revealed
bands at approximately 20 and 30 kDa for Aβ1−40, approximately 20, 30, 55 kDa, as
well as larger aggregates > 70 kDa for Aβ1−42. Furthermore, stronger signals indicated
that NT4X-167, though recognizing both AβpE3−40/42 and Aβ4−40/42, shows a prefer-
ence for the latter. Probing of a duplicate membrane with antibody 24311 revealed that
in fact Aβ4−40/42 migrated in a distinct single band of 50 kDa and do not readily form
oligomers of different molecular weight (Figure 3.1).
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Figure 3.1
Blue Native Western Blot of synthetic Aβ Peptides. Freshly dissolved syn-
thetic Aβ1−40/42, AβpE3−40/42 and Aβ4−40/42 were probed onto a nitr-
cellulose membrane. A Antibody NT4X-167 recognized both AβpE3−40/42
and Aβ4−40/42, with the latter migrating in distinct bands at approxim-
ately 50 kDa. B Antibody 1-57 showed strong recognition of AβpE3−40/42
exclusively. C Antibody IC16 recognized only Aβ1−40/42 D The polyclonal
antibody 24311 recognized all probed peptides, revealing that Aβ4−40/42
indeed migrated as single distinct bands of approximately 50 kDa without
any higher or lower molecular weight bands.
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3.2 characterization of the homozygous 5xfad model
3.2.1 Generation of Homozygous 5XFAD
Confirmed transgenic 5XFADhem males and females were set up as breeding pairs to
generate 5XFADhom animals. All animals of the resulting litters were screened for the
transgenes by conventional APP genotyping and animals found positive were further
analyzed by quantitative Real-Time PCR of genomic DNA as described. Homozygosity
was then verified by backcrossing with wild-type C57B6/J (WT). Confirmed 5XFADhom
individuals were then taken for further breeding. When breeding the 5XFADhom strain,
female mice were well propagating up to the age of approximately 4.5 months, male
animals up to the age of 8 months, with regular litter sizes between 5-8 pups. Female
5XFADhom mice had to be sacrificed due to ethical considerations at an age between
6-7 months and male 5XFADhom animals at the age of 9-10 months, because they dis-
played massive motor impairment and a generally poor condition at later stages.
3.2.2 Transgene Expression in young 5XFAD
Immunohistochemical analysis of young 5XFADhem and 5XFADhom revealed elev-
ated human APP expression in subiculum and cortex already at the age of 16 days
for the homo-zygous animals. This increased APP expression was persisting at the age
of 6 weeks (Figure 3.2). In order to compare the Aβ-distribution in cortex between
6 weeks old 5XFADhem and 5XFADhom mice, sagittal brain paraffin sections were
treated with the monoclonal antibody Aβ[N] (against N-terminal Aβ). In cortical layer
V cells, abundant punctate intracellular immunoreactivity was found (Figure 3.3),
which revealed a vesicular staining pattern at higher magnification (Figure 3.4).
59
Figure 3.2
Early age APP-expression in 5XFAD mice. Both 5XFADhem and 5XFADhom mice displayed
detecteable APP expression already at then age of 16 days (p16) in both subiculum and cortex,
with a more abundant APP-positive signal in the 5XFADhom. This finding persisted at 6 weeks
(6w) of age in both genotypes. Scalebar represents 50 µm for all images.
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Figure 3.3
Early age intracellular Aβ accumulation in 5XFAD mice. In 6-week old
5XFAD, intracellular accumulation of Aβ was detected with the antibody
Aβ[N] in the cortex (Right), with the 5XFADhom displaying a stronger Aβ
immunoreactivity than 5XFADhem. In the subiculum (Left), at this age no
intracellular Aβ was detected. Scalebar represents 50 µm for all images.
Figure 3.4
High magnification revealed a vesicular pattern of intracellular Aβ accumu-
lation in young 5XFAD mice. Scalebar represents 20 µm for both images.
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3.2.3 Amyloid-beta in older 5XFAD
To further verify the presence of N-terminally truncated Aβ and estimate relative
abundance of minor peptide isoforms in the 5XFAD model, a pooled sample of three
7-month-old female 5XFADhem individuals was subjected to IP followed by MALDI-TOF.
Besides Aβ1−40/42, several C-terminally and N-terminally truncated Aβ isoforms were
detected as described previously by Wittnam et al. (2012): AβpE3−42, Aβ4−42 and
Aβ5−42. Here, Aβ1−43, Aβ1−37, Aβ1−38, Aβ1−39 and Aβ4−40 were detected in addi-
tion to the previously reported ones as shown in figure 3.2.3.
Figure 3.5
Aβ isoforms in 5XFAD brain.
A Major species detected were Aβ1−40/42. B (Zoomed view of A) Less abundant
species detected in 5XFAD brains were Aβ1−43, Aβ1−37/38/39, Aβ4−40/42, and
Aβ5−42. C No peaks corresponding to Aβ were detected in the WT control.
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Table 3.1
Amyloid-beta Peptides detected between in 5XFAD brain by IP/MALDI-TOF
Peptide MonoisotopicWeight m/z Intensity Signal/ Noise
Aβ4−40 4012.04 4012.42 72.00 6.14
Aβ5−42 4049.09 4049.40 196.00 16.71
Aβ1−37 4071.99 4071.63 120.00 10.23
Aβ1−38 4129.01 4129.11 799.00 68.12
Aβ4−42 4196.16 4196.16 744.00 63.43
Aβ1−39 4228.08 4228.36 305.00 26.00
AβpE3−42 4307.21 4312.09 298.00 25.41
Aβ1−40 4327.15 4327.15 33683.00 2871.83
Aβ1−42 4511.27 4511.27 275605.00 23498.24
Aβ1−43 4612.32 4612.59 75.00 6.39
3.2.4 Phenotypical Characterization of Homozygous 5XFAD
The newly generated 5XFADhom strain was characterized regarding transgene expres-
sion pattern, Aβ expression, physical condition parameters and behavior phenotype
in comparison to both age-matched WT and age-matched 5XFADhem. The following
numbers of animals were used for the motor testing and behavior analysis: WT: n = 10
(2 months), n = 7 (5 months); 5XFADhem: n = 8-10 (2 months), n = 6-7 (5 months);
5XFADhom: n = 8-9 (2 months), n = 5-7 (5 months).
3.2.5 Physical Condition and Motor Abilities of Homozygous 5XFAD
At the age of two months, both 5XFADhem and 5XFADhom had a significantly reduced
body weight as compared to WT animals (both p < 0.001). At the age of 5 months,
5XFADhom again showed a significantly lower body weight as compared to both, WT
and 5XFADhem animals (both p < 0.01). However, no weight differences were observed
comparing 5XFADhem mice to WT animals (Figure 3.6).
As previously described (Jawhar et al., 2012), 5XFAD mice displayed a characteristic
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so-called clasping phenotype, an unusual retraction of fore- and hindlimbs when the
animal is suspended by the tail. Applying a clasping score scale ranging from 0-3 re-
vealed that in both genotypes revealed that this symptom is already present at the age
of 2 months, whereas WT mice showed no such motor impairment (both p < 0.05).
The clasping phenotype revealed progressing moto-neuronal impairment at the age of
5 months with significantly higher scores in 5XFADhem mice (p < 0.01) compared to
WT, and yet more aggravated impairment in 5XFADhom than in WT and 5XFADhem
(p < 0.001 and p < 0.05 respectively; Figure 3.7).
Figure 3.6
Body weight of 5XFAD mice at the age of 2 and 5 months. A At 2 months of age, both
5XFADhem and 5XFADhom displayed a significantly reduced body weight as compared to
WT control animals. B At 5 months, only 5XFADhom animals showed a reduced body weight
compared to both WT and 5XFADhem mice. (One-way ANOVA followed by Tukey´s post-hoc
test; *: p < 0.05; **: p < 0.01; ***: p < 0.001)
To analyze the sensory-motor performance, mice were subjected to the balance beam
and the string suspension task (Figures 3.8 and 3.9). In the balance beam task,
5XFADhom mice performed significantly poorer at the age of 5 months as compared to
age-matched WT and 5XFADhem animals (p < 0.001 and p < 0.05). In the string suspen-
sion test 5XFADhom performed worse than WT (p < 0.001) and 5XFADhem ( p < 0.05).
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Figure 3.7
Clasping phenotype of 5XFAD mice. A Whereas no clasping phenotype was observed for 2
month old WT animals, both 5XFADhem and 5XFADhom showed a characteristic retraction
of paws. B At 5 months of age, 5XFADhem showed a significantly aggravated clasping phen-
otype compared to WT controls that was even more pronounced in 5XFADhom, showing a
significantly higher clasping score than both WT and 5XFADhem animals. (One-way ANOVA
followed by Tukey´s post-hoc test; *: p < 0.05; **: p < 0.01; ***: p < 0.001)
3.2.6 Anxiety in Homozygous 5XFAD
Already at the age of two months, anxiety levels in 5XFADhom animals were signi-
ficantly lower compared to the age-matched 5XFADhem, as indicated by an increased
ratio of open versus total arm entries (p < 0.05). The average number of arm entries re-
mained unaltered (Figure 3.10, page 67). At 5 months, both 5XFADhem (p < 0.05) and
5XFADhom (p < 0.001) displayed altered anxiety behavior compared to WT controls,
with a more pronounced phenotype in the 5XFADhom group (p < 0.05 compared to
5XFADhem). The control parameter, i.e.the total number of arm entries was not signi-
ficantly different between all three groups (Figure 3.11, page 68).
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Figure 3.8
Sensory-motor performance of 5XFAD in the balance beam task. A No significant differences
were observed between the 2-month old groups. B 5-month old 5XFADhom animals performed
significantly worse than age-matched WT or 5XFADhem mice. (One-way ANOVA followed by
Tukey´s post-hoc test; *: p < 0.05; **: p < 0.01; ***: p < 0.001)
3.2.7 Working Memory Performance of Homozygous 5XFAD
No differences between all tested groups were found for the alternation rate, total num-
ber of arm entries, average speed in the maze and distance travelled in the cross maze
task, indicating that both 2 and 5 month old 5XFAD animals have no working memory
impairment independent of the genotype (One-way ANOVA followed by Tukey´s post-
hoc test; data not shown).
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Figure 3.9
Sensory-motor performance of 5XFAD in the string suspension task. A No significant dif-
ferences were observed between the 2-month old groups. B 5-month old 5XFADhom animals
performed significantly worse than age-matched WT or 5XFADhem mice. (One-way ANOVA
followed by Tukey´s post-hoc test; *: p < 0.05; **: p < 0.01; ***: p < 0.001)
Figure 3.10
Anxiety levels in the 5XFAD model. A At 2 months of age, the 5XFADhom animals showed
significantly reduced anxiety compared to the 5XFADhom group. B The number of total arm
entries was not significantly different between the groups (One-way ANOVA followed by
Tukey´s post hoc test, *: p < 0.05; **: p < 0.01; ***: p < 0.001)
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Figure 3.11
Anxiety levels in the 5XFAD model A At 5 months of age, the 5XFADhem animals showed
significantly altered anxiety compared to the WT group. The 5XFADhom animals showed signi-
ficantly reduced anxiety compared to the WT- as well as the 5XFADhom group. B The number
of total arm entries were not different between the groups (One-way ANOVA followed by
Tukey´s post hoc test, *: p < 0.05; **: p < 0.01; ***: p < 0.001)
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3.2.8 Spatial Reference Memory Impairment of Homozygous 5XFAD
To assess the spatial reference memory performance, WT, 5XFADhem and 5XFADhom
mice at 2 and 5 months were subjected to the morris water maze task. The initial cued
training phase, serving as a control experiment to exclude that sensory or motor
deficits bias the interpretation of the results, revealed that mice of all ages and geno-
types showed progressively decreasing escape latencies. 5 month old 5XFADhom an-
imals showed a significantly lower average swimming speed. However, no significant
difference in swimming speed at day 3 of the cued training phase was observed. There-
fore, all groups fulfilled the criteria for the task. In the following acquisition train-
ing phase, mice were forced to memorize an escape platform hidden below the water
surface during five days of training. Already at the age of 2 months, a significant
main genotype effect for the escape latency was evident (Repeated measures-ANOVA,
F = 7.405, p =0.05) for 5XFADhom, whereas no significant differences between 2-month
old WT and 5XFADhem mice were observed. However, significant differences over the
training days 1-5 were not evident at the age of two months (Figure 3.12). Again,
at the age of 5 months, there was a significant main effect for the genotype evident
(Repeated measures-ANOVA, F = 25.05, p < 0.001), with 5XFADhom showing a signi-
ficantly longer escape latency, although no differences in the swimming speed were
detected among the groups (One-way ANOVA, both p < 0.001). Furthermore, the es-
cape latency of 5XFADhom was significantly higher than that of WT animals at day 1
to day 5, and significantly different compared to the 5XFADhem group at days 2 and
3 of the acquisition training trial (Figure 3.13) On day 6 after start of the acquisition
training, mice were given a 30 s probe trial in which they were allowed to freely search
for the platform´s positon to assess spatial reference memory. Except for the group of
the 5-month-old 5XFADhom group, all genotypes and ages showed a clear, significant
preference for the target quadrant (Figure 3.14). The average proximity to the target
platform position did not differ significantly for the groups of 2-month-old animals
in the probe trial, whereas, in line with the loss of a target quadrant preference, the
average proximity to the target position was significantly lower in the 5 month old
5XFADhom group (Figure 3.14).
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Figure 3.12
Spatial reference learning in 2-month-old 5XFAD mice. A In the cued training phase, all
groups displayed significantly reduced escape latencies within a three-day timespan. B Similar
to A, in the acquisition training stage, all groups showed significantly reduced escape latencies
between day 1 and day 5 of the training. C, D In both cued training and acquisition training,
no differences in the swimming speed were observed. (A, B: Two-way ANOVA followed by
Dunnett´s post-hoc test for multiple comparison; C, D: One-way ANOVA followed by Dunnett´s
post-hoc test for multiple comparison; *: p < 0.05; **: p < 0.01; ***: p < 0.001)
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Figure 3.13
Spatial reference learning in 5-month-old 5XFAD mice. A In the cued training phase, all
groups displayed significantly reduced escape latencies within a three-day time span. B Dur-
ing the entire duration of the acquisition training stage, the 5XFADhom group showed a sig-
nificantly poorer performance in escape latencies than WT and 5XFADhem animals. C In the
cued training stage, 5XFADhom swam significantly slower than the WT and 5XFADhem group,
whereas D in the acquisition training, no differences for the swimming speed were observed.
(A, B: Two-way ANOVA followed by Dunnett´s post-hoc test for multiple comparison; C, D:
One-way ANOVA followed by Dunnett´s post-hoc test for multiple comparison; *: p < 0.05; **:
p < 0.01; ***: p < 0.001)
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Figure 3.14
Spatial reference memory of 5XFAD mice. A At two months of age, all tested groups showed
a significant preference for the target quadrant (T) over the left (L), right (R) and opposite (O)
quadrant (A, C, E). B, D Of the 5 month old groups, the WT and the hemizygous 5XFAD
animals showed a clear and significant preference for the target quadrant as well. F In the 5
month old homozygous animals, no significant preference was observed for the target quadrant.
(One-way ANOVA followed by Dunnett´s post-hoc test for multiple comparison; *: p < 0.05; **:
p < 0.01; ***: p < 0.001)
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3.3 passive immunization against n-truncated amyloid-beta
Female 5XFADhem were immunized for a duration of ten weeks with antibodies NT4X-
167 (termed NT4X-167 group), 1-57 (termed 1-57 group) and 9D5 (termed 9D5 group)
at a dosage of 10 mg/kg body weight. At the age of 7 months, mice were subjected
to behavioral testing and then sacrificed for biochemical analysis. The elevated plus
maze was performed first, followed by the cross maze task and then, after a one day
pause, mice were trained in the morris water maze paradigm, receiving the last of ten
injections approximately 6 hours prior to the the acquisition training trial. The experi-
mental approach compared three antibody-treated groups with a PBS-injected control
(termed PBS group). After the behavior testing, mice were sacrificed and further ana-
lyzed biochemically regarding plaque load and soluble/insoluble Aβ levels.
3.3.1 Quantification of Amyloid Plaque Deposits after Passive Immunization
The numbers of animals used for the passive immunization experiments were: (PBS-
group: 7; NT4X-167-group: 9; 1-57-group: 7, 9D5-group: 8). To exclude that the admin-
istered antibody would bias the plaque load detection, blind stainings (primary anti-
body incubation was skipped) were performed for all animals. The so-treated slices
were free of any immunoreactivity. Thus, plaque load measurement was not biased by
pre-existing immunoreactivity due to chronic passive administration of antibodies.
General Aβ plaque load levels were assessed by fluorescent Thioflavin S staining of
amyloid deposits. In the anterior motor cortex of mice immunized with the antibody
NT4X-167 there was a significantly (p < 0.05) lower plaque load compared to the PBS-
injected controls (PBS-group: 100.00 ± 14.10 %; NT4X-group: 61.20 ± 9.85 %). In the
thalamus, no significant differences of thioflavin S positive deposits were observed
between all groups. However, there was a trend towards a lower plaque burden for the
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Figure 3.15
Quantitative analysis of Thioflavin S-positive plaques in passively immunized 5XFAD mice.
A The plaque burden in the anterior motor cortex was significantly lowered in the NT4X-167
group compared to the PBS group, whereas no significant differences to the PBS group were
observed for the 1-57- and the 9D5 group B A trend, but no significant reduction in thioflavin
S-positive plaques was observed for the NT4X-167 group and the 9D5 group in the thalamus.
(One-way ANOVA followed by Dunnett´s post-hoc test for multiple comparison to the PBS
group, *: p < 0.05; **: p < 0.01; ***: p < 0.001)
NT4X-167 group and the 9D5 group with approximately 30 % (NT4X-167 group) and
20 % (9D5 group) lower measures compared to the PBS group (Figure 3.15 page 74).
The amount of AβpE3−X was measured by immunohistochemistry using the anti-
body 1-57. In the NT4X-group, a significantly lower plaque burden (-43.41 %) was
observed compared to the PBS group (PBS group: 98.47 ± 11.53 %; NT4X-167 group:
55.05 ± 7.09 %; p < 0.01). Similar as in the thioflavin S staining, lower plaque load (-
34.10 %) was seen for the NT4X-167 group in the thalamus, but, however, this trend did
not reach significance. Between all other groups, no significant differences were found
for both brain regions (Figure 3.16, page 75).
The levels of amyloid deposits reacting with the antibody NT4X-167 were not signi-
ficantly altered for any of the antibody treated groups compared to the PBS group in

































































































Quantitative analysis of AβpE3−X-positive plaques in passively immunized 5XFAD mice.
A The levels of plaques reacting with antibody 1-57 were significantly lower in the NT4X-167
group compared to the PBS group in the anterior motor cortex, whereas the 1-57 group and
the 9D5 group did show a plaque burden that was not significantly altered compared to the
PBS group. B For the thalamus there was a slightly lower, but not significantly different, plaque
load than in the PBS group found for the NT4X-167 group. Again, the 1-57 group and the 9D5
group were not different compared to PBS injected animals. (One-way ANOVA followed by
Dunnett´s post-hoc test for multiple comparison to the PBS group, *: p < 0.05; **: p < 0.01; ***:
p < 0.001)
Plaque load level determination using the antibody G2-10 reacting with AβX−40
revealed significantly lower plaque load for the NT4X-167 group compared to the PBS
group in the anterior motor cortex (PBS group: 100.50 ± 11.05 %; NT4X-167 group:
67.19 ± 7.90 %; p < 0.05), whereas the G2-10 reactivity in the 1-57 group and the 9D5
group remained unaltered. As seen before for the thioflavin S- and AβpE3−X stainings,
a slightly lower plaque load (-28.49 %) for the NT4X-167 group was also found in the
thalamus, but this trend did not reach significance. Thus, no significant differences
between the four groups were observed in the thalamus regarding AβX−40 reactivity
(Figure 3.18, page 77).
The plaque load levels for Aβ1−X as detected with the antibody 82E1 remained
indifferent between all four groups in both anterior motor cortex and thalamus (Figure
3.19, page 78). The same holds true for AβX−42 (detected with the polyclonal antibody
Abeta42) as shown in figure 3.20, page 78.
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Figure 3.17
Quantitative analysis of AβpE3−X- and Aβ4−X-positive plaques in passively immunized
5XFAD mice. A The average levels of plaques reacting with NT4X-167 was not significantly
altered for all three, the NT4X-167-, 1-57- and 9D5 group. B The same holds true for the thal-
amus. (One-way ANOVA followed by Dunnett´s post-hoc test for multiple comparison to the
PBS group, *: p < 0.05; **: p < 0.01; ***: p < 0.001)
3.3.2 Behavioral Phenotype of 5XFAD Mice after Passive Immunization
Following the plaque load analysis, the same groups were analyzed regarding their
behavioral phenotype in the cross maze and the elevated plus maze paradigm. Here,
likewise handled, PBS-injected WT (n = 7) animals were taken as an additional control
group.
Working Memory Performance of 5XFAD Mice after Passive Immunization
Compared to the PBS-injected WT animals, the PBS group showed significantly im-
paired working memory indicated by a reduced rate of correct alternations in the maze
(WT: 32.36 ± 3.60 %; PBS group: 19.94 ± 1.82 %; p < 0.05). None of the treatment groups
performed significantly different from the PBS group in this task as shown in figure
3.21, page 79. However, a significant t-test in comparison to the PBS group (p < 0.05)
indicated a trend towards a rescue of the working memory performance in the NT4X-
167 group. No such trend was, however, observed for the 1-57 group (t-test, p > 0.1),
which displayed higher variability, and the 9D5 group (t-test, p > 0.1), which performed
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Figure 3.18
Quantitative analysis of AβX−40-positive plaques in passively immunized 5XFAD mice. A
In the anterior motor cortex, the levels of plaques reacting with the antibody G2-10 was signific-
antly lower in the NT4X-167 group compared to the PBS group, whereas the average amyloid
burden of the 1-57 group and the 9D5 group was not different from the plaque load levels
observed in PBS-injected animals. B In the thalamus, none of the antibody injected groups was
significantly different from the PBS controls, though a trend towards lowered plaque load was
observed in the NT4X-167 group. (One-way ANOVA followed by Dunnett´s post-hoc test for
multiple comparison to the PBS group, *: p < 0.05; **: p < 0.01; ***: p < 0.001)
almost indentical to the PBS group. The control parameters, i.e. average distance trav-
elled and average speed in the maze, were not significantly different for any of the
treatment groups compared to the PBS injected animals (data not shown).
Anxiety Phenotype of 5XFAD Mice after Passive Immunization
In the elevated plus maze, importantly, the PBS-group was found to perform almost
as described previously in Jawhar et al. (2012), displaying significantly different per-
centage of time spent in the open arms than the PBS-injected WT control group (p <
0.05) (Figure 3.21 B, page 79). No significant alteration in anxiety behavior has been
observed for the antibody-treated groups. The ratio of open arm and total arm entries
as well as the average speed and distance travelled were not significantly different
comparing the treatment groups to the PBS injected 5XFAD controls (data not shown).
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Figure 3.19
Quantitative analysis of Aβ1−X-positive plaques in passively immunized 5XFAD mice. A
The levels of plaques reacting with antibody 82E1 were not significantly different between all
groups compared to the PBS group in the anterior motor cortex. B The same holds true for the
thalamus. (One-way ANOVA followed by Dunnett´s post-hoc test for multiple comparison to
the PBS group, *: p < 0.05; **: p < 0.01; ***: p < 0.001)
Figure 3.20
Quantitative analysis of Aβ42-positive plaques in passively immunized 5XFAD mice. None
of the antibody-injected groups showed significantly altered levels of antibody Abeta42-positive
amyloid plaques in the anterior motor cortex and B the thalamus. (One-way ANOVA followed
by Dunnett´s post-hoc test for multiple comparison to the PBS group, *: p < 0.05; **: p < 0.01;
***: p < 0.001)
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Figure 3.21
Working memory performance and anxiety behavior of passively immunized 5XFAD mice.
A The PBS group showed significantly impared working memory in the cross maze paradigm
in comparison to the PBS-injected WT control animals. The performance of the antibody-treated
groups was not significantly different from the PBS-injected 5XFAD group, however, a positive
trend was observed for the NT4X-167 injected mice. B Compared to PBS-injected WT controls,
PBS-injected 5XFAD showed a reduced anxiety phenotype as shown by the significantly in-
creased time exploring the open arms of the paradigm, whereas none of the antibody-treated
groups was significantly different from the PBS-injected 5XFAD controls. (One-way ANOVA
followed by Dunnett´s post-hoc test for multiple comparison to the PBS group, *: p < 0.05; **: p
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4.1 characterization of the antibody nt4x-167
To investigate distinct Aβ species, specific antibodies are a valuable research tool. The
monoclonal antibody NT4X-167 (IgG2b; official name of the cell line Aβ4−40 NT4X-167;
DSM ACC3162) was raised against unconjugated Aβ4−40 by immunization of Balb/c
mice and antibody-producing cells were fused with the myeloma cell line P3-X63-Ag8
to generate hybridoma cells. The antibody was generated to specifically recognize an
N-terminal epitope of oligomeric Aβ4−40 and was selected to bind to amino acids 4-10
of the Aβ sequence and with Aβ4−40 but not with amino acids 36-40. It was shown
subsequently, that the phenylalanine at position four is essential for target engagement
by NT4X-167. NT4X-167 is the first antibody reacting with Aβ4−X (Antonios et al.,
2013).
Toxic Aβ oligomers have increasingly gained attention during the past years. AβpE3−42
and Aβ4−42 have been shown to rapidly form stable oligomers whereas Aβ1−42 rather
stays in equilibrium with the monomeric state (Bouter et al., 2013). It has been proposed
that the N-terminal truncation of Aβ triggers a disequilibrium of monomers and oli-
gomers leading to increased levels of oligomers, which in turn trigger neuropathologic
alterations (Bayer and Wirths, 2014). Varying terminal end lenghts have been reported
to alter the aggregation properties of Aβ (Bouter et al., 2013; Jan et al., 2008; Jarrett
et al., 1993; Pike et al., 1995b). Thus, combinatory effects of varying terminal ends
might determinine the stability and solubility of Aβ oligomeric assemblies.
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In fact, this Aβ4−X aggregation pattern observed in Western Blot under blue native
conditions was clearly different from that observed for Aβ1−40/42 and AβpE3−40/42.
These experiments revealed that NT4X-167 recognizes AβpE3−40/42 and Aβ4−40/42,
of which the latter migrated as a single band at approximately 50 kDa (see 3.1, 57). In
a different approach, Bouter et al. (2013) reported a high propensity of Aβ4−42 to form
stable oligomers as well. In contrast, pyroglutamate AβpE3−40/42 ran as oligomers of
different sizes including higher molecular weight oligomers formed by AβpE3−42 and
Aβ1−42.
In addition, varying N-terminal length seemed to account somehow for different
SDS-resistance of Aβ4−X: In Western Blot under reducing conditions we found that
AβpE3−40 and Aβ4−40 migrated as monomers and dimers, whereas AβpE3−42 and
Aβ4−42 produced trimers and tetramers in addition (Antonios et al., 2013), as it was
shown previously (Masters et al., 1985; Wirths et al., 2010c). Solubility/aggregation
propensity of N-terminally intact Aβ has previously been reported to depend on the
carboxy-terminal of the peptide (Jan et al., 2008; Jarrett et al., 1993). Here, unlike the pat-
tern observed under reducing conditions, Aβ4−42 showed aggregation to oligomers of
identical size as Aβ4−40 under native consitions. In contrast, for AβpE3−42 and Aβ1−42
formation of higher molecular weight oligomers was observed in this approach.
In human AD tissue, NT4X-167 revealed an interesting affinity pattern, staining CAA
preferentially but barely reacting with extracellular plaques (Antonios et al., 2013). Sim-
ilarly, this has been described previously for the anti-AβpE3−X conformation-specific
antibody 9D5 that reacts with lower molecular weight oligomers exclusively (Wirths
et al., 2010c). In murine tissue, NT4X-167 reacted with both intracellular Aβ aggreg-
ates and extracellular amyloid deposits (Antonios et al., 2013).
We have further shown that Aβ4−42 is cytotoxic and that NT4X-167 rescued Aβ4−42-
but not AβpE3−42- and Aβ1−42-induced cytotoxity (Antonios et al., 2013) in a cell
culture model. This further underlines the importance of toxic oligomers composed of
Aβ starting at residue 4.
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These experimental findings point to the conclusion that the newly developed mono-
clonal antibody NT4X-167 is selective for N-truncated Aβ, with a preference for Aβ4−X,
and could have potential to investigate its role in vivo. Moreover, Western Blotting of
synthetic peptides revealed that under native conditions, Aβ4−40/42 display an oli-
gomer aggregation pattern that is different from Aβ1−40/ Aβ1−42 and AβpE3−40/42,
which further supports structural differences of Aβ4−X asseblies as previously repor-
ted in Bouter et al. (2013). The migrating pattern under native conditions indicated that
Aβ4−X is more prone to form stable oligomeric assemblies. It has been demonstrated
for Aβ1−40 and Aβ1−42 that presence of the previous interferes with aggregation of
the latter (Jan et al., 2008). Interaction of N-truncated AβpE3−42 with Aβ1−42 has been
shown to alter conformation and increase toxicity of hetero-oligomers (Nussbaum et al.,
2012), and the existence of a distinct oligomeric species of AβpE3−X, possibly of par-
ticular interest for AD diagnosis and therapy, has been demonstrated by Wirths et al.
(2010c). The observation that NT4X-167 barely reacts with densely aggregated plaques
in AD Antonios et al. (2013) indicates that, probably due to a similar effect of Aβ4−X,
NT4X-167 prefers a more soluble oligomeric conformation of Aβ aggregates. However,
if and how Aβ4−X isoforms display similar effects is yet unknown.
NT4X-167 is the first monoclonal antibody reacting with Aβ4−X and therefore rep-
resents a valuable tool to investigate the mechanism and consequences of an altered
equilibrium between soluble and insoluble Aβ induced by N-terminal truncation of
Aβ. It has been shown that in vitro NT4X-167 rescues Aβ4−42 induced cytotocity (Ant-
onios et al., 2013). In summary, this raises the interest in NT4X-167 as an experimental
and possible therapeutic tool.
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4.2 characterization of homozygous 5xfad mice
4.2.1 Generation of the Mouse Line
The 5XFAD model is a transgenic mouse line overexpressing human APP and human
PS-1 with a total number of five familial AD mutations that are inherited together. This
leads to massive and rapid accumulation of amyloid plaques and elevated AβX−42
levels in the brain. 5XFAD was described previously as one of few models displaying
a combination of several major hallmarks of human AD including neuron loss (Eimer
and Vassar, 2013; Jawhar et al., 2012; Oakley et al., 2006). Neuronal loss is a feature that
has not been reported for some other commonly used APP transgenic models such
as the PDAPP (Games et al., 1995), Tg2576 (Hsiao et al., 1996) and the APP/PS1∆E9
models (Borchelt et al., 1997). The 5XFAD model displays accumulation of intracellular
Aβ prior to plaque formation as early as at 6-8 weeks of age in the subiculum and
furthermore in cortical layer V, a region where abundant neuron loss is observed at
later stages (Jawhar et al., 2012; Oakley et al., 2006). This feature of early intracellular
Aβ accumulation has, among others, been described for several AD models including
APPSDL/PS1M146L (Wirths et al., 2001), APPSL/PS1M146L (Wirths et al., 2002), Tg2576
(Takahashi et al., 2002), 3xTg (Oddo et al., 2003) or APP/PS1KI (Casas et al., 2004).
The focus of the present study lay on N-terminally truncated Aβ: It was described
previously that besides full length Aβ, minor species such as AβpE3−X (Frost et al.,
2013; Wittnam et al., 2012), Aβ4−X and Aβ5−42 (Wittnam et al., 2012) are present in the
5XFAD model . AβpE3−X species have also been shown to be present in brains of mur-
ine models, canines, non-human primates as well as in human AD brain samples (Frost
et al., 2013; Mori et al., 1992). It was further shown that AβpE3−X represents a major
fraction in human AD brain (Portelius et al., 2010; Saido et al., 1995). N-terminally trun-
cated AβpE3−X has gained much attraction since then and it was further described that
increased levels of AβpE3−X aggravate the behavioral phenotype whereas a knock-out
of glutaminyl cyclase, the enzyme responsible for pyroglutamate formation, rescues
behavioral deficits (Jawhar et al., 2011; Wittnam et al., 2012).
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However, although it was described as early as in 1985 (Masters et al., 1985), and it
was shown to be relatively abundant in brains of AD and vascular dementia patients
(Lewis et al., 2006), Aβ starting at position four did not received likewise attention. As
well, not much is known about Aβ starting at position 5. It has been shown to be depos-
ited in human AD brain and to be produced due to caspase activity (Murayama et al.,
2007; Takeda et al., 2004). More recently, a new, Aβ4−42-expressing model (Tg4-42) dis-
playing abundant neuron loss and behavioral deficits amyloid deposition was created
(Bouter et al., 2013). In contrast to prominent intracellular Aβ-immunoreactivity, no
extracellular amyloid deposition was described for Tg4-42 mice (Bouter et al., 2013).
Besides these N-terminally ragged Aβ peptides, several C-terminally truncated spe-
cies such as AβX−38 have been also described in mouse models, familial and sporadic
AD cases (Karran et al., 2011; Moro et al., 2012). It was shown that AβpE3−X correlates
better with cognitive decline in human AD than does plaque deposition (Holtzman
et al., 2011). In contrast to the findings in AD, N-truncated Aβ represents a minor
fraction in 5XFAD (Wittnam et al., 2012). This raised the question if and to what ex-
tent 5XFAD represents a suitable model to investigate the pathophysiologic effects of
N-truncated Aβ variants. In fact, some APP overexpressing models have not been re-
ported to show neuron loss (e.g. PDAPP, APP/PS1∆E9, Tg2576; table 4.1, page 95),
which is a feature of AD (Blennow et al., 2006). Together with this, the remarkably dif-
ferent Aβ stoichiometry observed somehow questions the validity of commonly used
models.
To address this issue, a homozygous 5XFAD line was created to increase the trans-
gene expression and elevate the Aβ levels in the animals brains. Breeding transgenic
mouse models of AD to homozygosity is a common procedure to aggravate the extent
of the phenotype and accelerate its progression and has been performed previously
for models such as PDAPP (German et al., 2003), ARTE10 (Willuweit et al., 2009) and
Tg4-42 (Bouter et al., 2013). The consequences of homozygosity and related findings
will be discussed in the following subsections.
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4.2.2 Transgene Expression in young 5XFAD
Immunohistochemistry on parrafin sections of young 5XFADhem and 5XFADhom mice
revealed that both APP expression (at postnatal day 16 and persisting at the age of
six weeks) and Aβ production (in six weeks old mice) is elevated in the 5XFADhom
animals compared to 5XFADhem mice (Figures 3.2, page 60 3.3, page 61 3.4, page
61). To determine the effects of the elevated transgene expression, the 5XFADhom strain
was thoroughly characterized at later ages subsequently.
4.2.3 Prevalence of N-truncated Amyloid-beta in young 5XFAD
Based on the observation that indeed the levels of Aβ are elevated in 5XFADhom mice,
we performed immunohistochemstry on brain sections of six weeks old 5XFADhom
animals to investigate whether AβpE3−X, Aβ4−X and Aβ5−X can be detected at this
early time point. Employing the newly developed antibody NT4X-167 recognizing both
AβpE3−X and Aβ4−X in combination with the antibody 1-57 specifically reacting with
AβpE3−X, we could show abundant intracelluar NT4X-167 reactivity in the 5XFADhom
animals in contrast to no detecteable AβpE3−X-immunoreactivity. This immunohisto-
chemical pattern was not found in 5XFADhem animals of the same age, indicating
that an high transgene expression levels are crucial for detection of underrepresented
Aβ species in young 5XFAD. Immunohistochemistry did not reveal any extracellular
AβpE3−X in 6 weeks old 5XFAD. This observation led to the conclusion that in the
5XFAD model, Aβ4−X precedes AβpE3−X (Antonios et al., 2013). Later Appearance
of AβpE3−X in this model is further supported by Frost et al. (2013), who found no
AβpE3−X immunoreactivity in 2.5-month-old 5XFAD. Importantly, Aβ4−X was detec-
ted together together with Aβ1−X in the neurons of cortical layer V that are prone to
degenerate in 5XFAD mice at the age of 12 months (Jawhar et al., 2012; Oakley et al.,
2006). Such transient intraneuronal Aβ correlated with subsequent neuron loss has also
been reported for several other APP/Aβ models (Alexandru et al., 2011; Bouter et al.,
2013; Casas et al., 2004; Christensen et al., 2008, 2010a; Wirths et al., 2009).
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Several reports found intracellular accumulation of Aβ in AD, too (D’Andrea et al.,
2001, 2002; Fernandez-Vizarra et al., 2004; Mochizuki et al., 2000). It has been shown
that this intracellular accumulation takes place in AD-vulnerable regions (Gouras et al.,
2000).
Similarly, we performed stainings for Aβ5−X employing the polyclonal antibody AB5-3
to elucidate whether this N-truncated variant is also present at this time point. In con-
trast to Aβ4−X, Aβ5−X does not appear to be abundantly produced in six weeks old
5XFADhom mice, since no intracellular aggregates or extracellular amyloid plaques
were detected with AB5-3 at six weeks of age (Guzman et al., 2014). The feature of
intracellular Aβ accumulation preceeding plaque deposition in this model is well in
line with the findings in AD. Assuming that intracellular Aβ accumulation represents
a pathologic key event, the finding of early intraneuronal Aβ4−X suggests that this
isoform might contribute to neurodegenerative processes, which is in line with obser-
vations in the newly generated Tg4-42 model (Bouter et al., 2013).
4.2.4 Amyloid-beta in 7-month-old 5XFAD
In order to assess whether minor ragged Aβ variants are also present in older 5XFAD
and to further validate the findings from immunohistochemistry, I performed a com-
bined IP/MALDI-TOF approach on brain tissue homogenates from 7-month-old 5XFAD.
Using a mixture of the antibodies 4G8 and 6E10 coupled to paramagnetic Dynabeads,
Aβ was precipiated from neutralized formic acid extracts of the brain homogenate.
The MALDI-TOF detection enabled for identification of peaks corresponding to a total
number of ten Aβ peptides. Among these, as described earlier, Aβ1−40 and Aβ1−42
were detected with the highest intensity peaks (Wittnam et al., 2012), with the latter sig-
nal being approximately 10-fold more intense than the peak for Aβ1−40. As described
in Wittnam et al. (2012) for six month old mice, the less abundant peptides Aβ4−42,
AβpE3−42 and Aβ5−42 were detected. Beyond the findings from Wittnam et al. (2012),
the IP/MALDI-TOF approach with 4G8/6E10 described here revealed the presence of
Aβ4−40, Aβ1−37, Aβ1−38, Aβ1−39, AβpE3−42 and Aβ1−43.
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Since this MALDI-TOF approach can be biased by several factors such as the choice
of the antibodies for IP, it is not suitable for an accurate quantification of the single Aβ
peptides. However, since the selected antibodies both recognize central linear epitopes
within the Aβ sequence (which likely minimizes the bias of preferential binding), the
peak intensities allow for a rough estimation of the relative abundance of the peptides.
Of the minor species detected, the Aβ4−42 and Aβ1−38 were most abundant as in-
dicated by peak intensity. This is in line with the previous finding that in 5XFAD mice
Aβ4−X is detectable at earlier time points than AβpE3−X and further supports the view
that the minor species Aβ4−X may play an important role in the progress of pathologic
alterations in this model (see also table 3.2.3, page 62; Antonios et al. (2013)).
Taken together, 5XFAD represents a model with early-life expression and intracellular
accumulation of Aβ4−X, a peptide that is expressed and accumulated continously up
to the age of 7 months. In addition, it expresses AβpE3−X, Aβ5−X and other minor
Aβ isoforms. The most abundant peptides produced are, however, Aβ1−40/42, which
does not resemble the stoichometry of the different Aβ peptides found in human AD,
where N-terminally truncated Aβ has been reported to be highly abundant or even
the major fraction in brains of AD patients (Kawarabayashi et al., 2001; Portelius et al.,
2010; Saido et al., 1995). Nevertheless, 5XFAD produces a heterogenous mixture of Aβ
that comprises the major species found in AD patients.
4.2.5 Gene Dosage-dependent Effects in the 5XFAD Model
For a detailed investigation of gene-dose effects, 5XFADhem and 5XFADhom mice were
compared to WT animals regarding their behavior phenotype (see 3.2.6 ff, page 65 ff)
and the course of amyloid pathology in animals. Whereas 5XFADhem mice have been
reported previously to show behavior impairment in the elevated plus maze and the
cross maze at the age of 6 months (Jawhar et al., 2012) and spatial reference memory
deficits when 12 months old (Bouter et al., 2014), the onset of behavior deficits is con-
siderably shifted towards earlier time points in the 5XFADhom strain. Anxiety behavior
is significantly altered already at 2 months of age compared to the 5XFADhem group.
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This early onset and genotype dependent aggravation of behavior deficits is persisting
at the age of 5 months, where 5XFADhem, 5XFADhom and WT groups showed clear
and significant differences in their tendency to explore the open arms of the maze. In
the water maze, an overall effect of the genotype on the escape latency was detecteable
already at the age of 2 months, and a robust significant impairment of the spatial ref-
erence memory was evident at the age of 5 months for the 5XFADhom group, whereas
age-matched 5XFADhem showed no impairment in this task. The shift of behavioral
impairment to an earlier onset was accompanied by a likewise aggravation of other
alterations typically observed in 5XFAD such as reduced body weight, and faster devel-
opment of a motor phenotype, indicated by higher clasping scores and poorer perform-
ance in the balance beam and the string suspension task for 5XFADhom. Importantly,
at an age 2 of months, 5XFADhom animals displayed first behavioral alterations but
no significant aggravation of their motor phenotype compared to the 5XFADhem trans-
gene group. Therefore, the accelerated development of impaired behavior precedes the
manifestation of aggravated motor deficits.
In Richard et al. (2015), we have further shown that, along with the accelerated devel-
opment of behavioral impairment, the levels of both extracellularly deposited amyloid,
soluble and insoluble Aβ are significantly elevated in the 5XFADhom groups compared
to the respective 5XFADhem groups: A significant increase of the amyloid plaque bur-
den was noted in cortex (+ 332 %), hippocampus (+ 715 %) and thalamus (+ 411 %) of 2
month old 5XFADhom. The same holds true for 5 month old animals (+ 328 %, + 564 %
and 201 % respectively) as well as for 9 month old male 5XFADhom (+ 32 %, + 52 % and
+ 75 %) (experiments performed by Anastasiia Kurdakova using the antibody Aβ[N]).
Interestingly, the relative plaque load was found to increase slower with aging which
might reflect a saturation effect. This is in line with the initial description of the model,
which, although not quantified, indicated a slower increase of the amyloid pathology
between the analyzed 6- and 9 month old groups (Oakley et al., 2006). Similar observa-
tions were also reported for the APP/PS1KI and the PDAPP models which also exhibit
an abundant plaque pathology but a plateau in deposition without significant increase
in amyloid burden (DeMattos et al., 2012; Wirths et al., 2010a).
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A plateau stage has also been described for AD (Jack et al., 2013). Plaque load quanti-
fication experiments were performed by my colleague Anastasiia Kurdakova.
In addition, we subjected whole-brain lysates (TBS and SDS-fraction) of 2- and 5 month
old animals to quantitative ELISA measurement and found significantly elevated levels
of soluble and insoluble Aβ1−42 and insoluble Aβ1−40 in 5XFADhom animals (2 and 5
months) compared to age-matched 5XFADhem (ELISA measurements were performed
by Sandra Baches, Dept. of Neuropathology, Heinrich Heine Universität Düsseldorf,
Germany). These findings are consistent with the increased plaque burden observed
for 5XFADhom (Richard et al., 2015).
Besides the described acceleration of amyloid plaque deposition and the increased
levels of soluble and insoluble Aβ levels, we could also demonstrate that 5XFADhom
at 9 months show significantly increased axonal degeneration. This was assessed by
immunohistochemistry on brain and spinal cord sections employing the antibodies
against NF200 (a neurofilament subunit) that revealed disclosed marked axonal swell-
ings, mainly large axonal spheroids that were independent from plaques (Experiments
performed by my colleague Anastasiia Kurdakova). The number of these dilatations
was significantly increased for 5XFADhom mice compared to 5XFADhem animals in
both pons and spinal cord gray matter (Richard et al., 2015). Such an age-dependent
axonopathy in brain and spinal cord of 5XFAD has been reported previously (Jawhar
et al., 2012) and spinal cord pathology including formation of amyloid plaques has
been reported in other mouse models overexpressing mutant APP (Christensen et al.,
2014; Seo et al., 2010; Wirths et al., 2006, 2007; Yuan et al., 2013).
In summary, increasing the transgene dose in 5XFAD leads to increased expression
of APP/Aβ, a significant aggravation of pathology and a considerably earlier onset
of related behavioral alterations. The early onset of spatial memory deficits suggests
that 5XFADhom represents a well-suited model for preclinical studies within short
time frames. It might moreover especially facilitate the analysis of intracellular Aβ,
truncated isoforms in particular, as investigation of young 5XFADhom was imperative
to detect early accumulation of intracellular Aβ4−X.
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4.3 5xfad in comparison to other models
The 5XFAD model represents one of the most thoroughly investigated transgenic mod-
els of AD and the knowledge about it has been further broadened here. Together with
the APP/PS1KI model, 5XFAD exhibits a very early onset of plaque pathology at the
age of two months that is preceeded by intracellular accumulation of intracellular Aβ.
N-terminally truncated Aβ has been reported in various other mouse models: Aβ pep-
tides starting at position 2/3 and position 4/5 have been reported for the APP/PS1KI
model (Casas et al., 2004). AβpE3−X and Aβ2/3−40 have been described in the APP23
mouse (Schieb et al., 2011). APP/PS1∆E9 expresses AβpE3−X an the age of 6 months
and is accessible as a therapeutic target (Frost et al., 2012, 2013). Less is known about
N-terminally truncated Aβ in PDAPP, however, passive immunization of PDAPP with
an AβpE3−X-specific antibody reduced insoluble Aβ, indicating the presence and ac-
cessibility of at least AβpE3−X (DeMattos et al., 2012). The Tg2576 model has been
proven to produce AβpE3−X, too (Kawarabayashi et al., 2001). An important disadvant-
age of the APP/PS1KI model, which shows a similar phenotypical progression as that
of 5XFAD, is that it has to be maintained with two parental lines because the APP-
and PS transgenes do not co-segregate (Casas et al., 2004). Other, more recently de-
veloped models are exclusively expressing N-truncated AβpE3−42 and Aβ4−42 which
makes them valuable tools to investigate N-truncated Aβ in particular. Both display
a strinking phenotype including intracellular Aβ aggregation, behavioral impairment
and neuron loss (Bouter et al., 2013, 2014; Meissner et al., 2014; Wittnam et al., 2012).
However, in passive immunization studies, analysis of these models showing no plaque
deposition would be complicated as plaque load has been a well-accepted and widely
used measure in immunotherapeutic approaches (Bard et al., 2000; DeMattos et al.,
2001, 2012; Frost et al., 2012; Wirths et al., 2010c). The rapid onset and progression of
the phenotype in 5XFAD animals further offers time advantages over other commonly
employed models like Tg2576 (Hsiao et al., 1996), PDAPP (Games et al., 1995) and
APP/PS1∆E9 (Borchelt et al., 1997) and APP23 (Sturchler-Pierrat et al., 1997) which
show a considerably later onset of plaque deposition and intracellular Aβ.
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Moreover the AD feature of neuron loss (Blennow et al., 2006) has not been reported
for PDAPP, APP/PS1∆E9 and Tg2576. An overview of the mentioned APP transgenic
models in comparison to 5XFAD is presented in table 4.1, page 95.
Is the 5XFAD Model Suitabe to Study N-truncated Amyloid-beta?
5XFAD meets essential assumtions of the modified amyloid cascade hypothesis with
neuron loss in regions that accumulate intracellular (N-truncated) Aβ and offers time-
advantage due to its rapid phenotypical progression compared to other models. It
is easy to maintain due to co-segregation of the APP and PS-1 transgenes which
gives it advantage over another model displaying rapid development of pathology
(APP/PS1KI). These facts support the choice of 5XFAD for the passive immunization


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4.4 passive immunization against n-truncated amyloid-beta
Passive immunization with various antibodies against Aβ has been widely studied
since the first successful approach by Bard et al. (2000) (A representative subset of
chronic passive immunization approaches is summarized in appendix table 4.2, pages
115 ff). Some studies suggested a significant reduction of pre-existing plaques in trans-
genic mice (Frost et al., 2012; Wilcock et al., 2004b,c, 2006), however others discussed
that clearance of pre-existing plaques is limited (Tucker et al., 2008) or did not occur
after passive immunization (Dodart et al., 2002; Levites et al., 2006). On the contrary,
evidence for a plaque-preventative effect of administered anti-Aβ antibodies was fre-
quently reported (Bard et al., 2000, 2003; Bussiere et al., 2004; DeMattos et al., 2001,
2012; Frost et al., 2012; Levites et al., 2006; Lord et al., 2009b). In vivo antibody effects
were not restricted to alterations in the amyloid plaque burden: In a subset of passive
immunization experiments it was shown that antibody-administration led to increased
vascular amyloid (DeMattos et al., 2012; Racke et al., 2005; Schroeter et al., 2008; Wil-
cock et al., 2004c, 2006).
It has been proven difficult to translate the success of preclinical passive immuniz-
ation trials into clinic. For instance, Bapineuzumab, the humanized equivalent of the
3D6 antibody investigated first in Bard et al. (2000), showed some target engagement
but the treatment did not benefit patients. (Lannfelt et al., 2014). Solanezumab, the
humanized equivalent to the antibody 266 (DeMattos et al., 2001) was not reported
to have significant effects in patients as well. Whereas trials on bapineuzumab were
terminated, investigation of solanezumab in clinical trials is driven further currently.
Furthermore, side effects such as increased occurence of microhemorrages have been
reported after passive immunization of mice against Aβ (DeMattos et al., 2012; Racke
et al., 2005; Schroeter et al., 2008; Wilcock et al., 2004c, 2006), even in a subchronic
approach with few doses only (Lee et al., 2005). Importantly, the observation of side
effects in preclinical studies was somehow predictive of severe adverse events that led
to halting of some human clinical trials (Lannfelt et al., 2014). This was despite of some
preclinical approaches showing both a significant rescue or amelioration of behavioral
and/or memory impairment in transgenic mice and induction of side effects in the
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same cohorts (Wilcock et al., 2004c, 2006). However, the overall outcome of clinical
passive immunization studies targeting Aβ was much less promising than results from
murine trials suggested (Lannfelt et al., 2014). These numerous studies taken together
point out a need to find a more specific and safer immunotherapeutic approach for
AD. In the course of this it has been proposed that N-terminally truncated Aβ might
represent a suitable target for immunotherapy.
Two recent studies addressing this hypothesis (DeMattos et al., 2012; Frost et al.,
2012) share the idea of passively immunizing mice against N-truncated Aβwith the cur-
rent study but differ from previous studies, each other and the present one in a variety
of parameters which are 1) the antibodies used for immunization, 2) the animal model
employed and 3) the administration in regard of both dosage and time course. These
factors are likely to influence the outcome of passive immunization trials: Frequently
used animal models display different Aβ stoichiometry and morphology of amyloid
deposits, e.g. PDAPP and Tg2576 mice (Fryer et al., 2003; Hsiao et al., 1996; Sasaki
et al., 2002). Unlike some other models, the 5XFAD mouse carries several mutations
that elevate AβX−42 levels disproportionally (Oakley et al., 2006), and APP23 mice are
notable for abundant vascular amyloid desposition. Different monoclonal antiobodies
have been shown to have highly different potential for preventative and therapeutic
approaches (DeMattos2012) and the induction of side effects and alterations of plaque
load levels has been shown to be dose-dependent (DeMattos et al., 2012; Schroeter et al.,
2008). Some studies on passive immunization found diverging results when analyzing
extracellular plaque burden and total levels of Aβ peptides in brain lysates (DeMattos
et al., 2012; Frost et al., 2012). This complicates inter-experimental comarison and un-
derlines the importance of conducting comparative experiments as in the present study.
To address the questions whether a) Aβ4−X and/or AβpE3−X are contributing to the
etiology of the disease-like phenotype in the 5XFAD mouse model and b) NT4X-167
might be suitable as a therapeutic tool, a pilot study comparing three different mono-
clonal antibodies (IgG2b) against N-truncated Aβ was conducted. Female 5XFADhem
mice were injected with 10 mg/kg body weight of NT4X-167, antibody 1-57 (recogniz-
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ing AβpE3−X exclusively, independent of conformation, (Wirths et al., 2010a), see also
3.1, page 57) or antibody 9D5 which reacts with low molecular weight oligomers of
AβpE3−X exclusively (Wirths et al., 2010c). PBS-injected 5XFAD animals served as a
control in this study. The experimental setup chosen here was essentially based the ap-
proach of Wirths et al. (2010c), to treat a well-described model (5XFAD) with abundant
amyloid pathology, behavioral deficits and fast phenotypical progression in a compar-
ative approach with three different antibodies. The treatment duration was prolonged
to assess potential effects on behavior in the animals at a time point were the behavioral
impairment is more manifest, somewhat later than the time point where they become
visble at first (6 months; Jawhar et al. (2012)).
In contrast to the current study, both therapeutic trials conducted in DeMattos et al.
(2012) and Frost et al. (2012) and the preventative trial of DeMattos et al. (2012) were ini-
tiated at time points where the behavioral phenotype is already manifest (see 4.1, page
95). The preventative treatment of Frost et al. (2012) started at the age of 5.8 months,
only little before first behavioral impairment for APP/PS1∆E9 model become visible
(6 months). In both publications, no behavioral data have been reported which makes it
impossible to conclude whether the antibody administration had effects beyond clear-
ance of Aβ.
In general has the majority of chronic passive immunization studies investigated either
prevention of amyloid deposition at early stages or aimed to remove plaques at very
late stages. To date, few studies described a mid-stage approach of anti-Aβ passive im-
munization (DeMattos et al., 2012; Schroeter et al., 2008; Wirths et al., 2010c). In human
AD, plaque deposition starts decades before the onset of clinical symptoms and is vir-
tually at maximal levels by time of diagnosis (Jack et al., 2010; Morris and Price, 2001;
Price et al., 2009), patients with mild cognitive impairment due to AD are therefore at
a stage well after disease initiation. Thus, the majority of preclinical studies focusing
on prevention of amyloid deposition or removal of pre-existing plaques, investigated
stages that are reminescent of the disease onset prior to diagnosis or very late symp-
tomatic stages of AD. For a very early intervention in AD by passive immunization, it
would be necessary to identify patients that are likely to develop the disease. Unless for
the rare cases of familial AD, to date biomarkers that allow for identification of patients
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before they develop amyloid deposits/cognitive symptoms are lacking. It is therefore
impossible to clearly distinguish individuals that will remain healthy from those that
will convert to a cognitively impaired phenotype (Fiandaca et al., 2014). Therefore,
even if very early therapeutic invention has significant effects in a preclinical study as
in Frost et al. (2012), it is hardly possible to design studies translating this approach
into clinical trials. Opposite to the prevention of amyloid deposition, the majority of
therapeutic trials in mice does reflect a stage of fully-blown AD with abundant plaques
in the brain and advanced cognitive impairment.
In contrast to abundantly untertaken preventative and late-stage therapeutic approaches,
such as those performed by DeMattos et al. (2012) and Frost et al. (2012), the 5XFAD
mice treated in the present study already had considerable levels of deposited amyloid
plaques at the starting point of immunization, but were at an age before onset of beha-
vioral symptoms. The present study therefore likely reflects an approach closer to late
preclinical or early symptomatic AD.
4.4.1 Chronic Passive Immunization of 5XFAD Mice
In the NT4X-167 group, Thioflavin S staining for fibrillar Aβ aggregates (Bussiere et al.,
2004) revealed lowered levels compared to PBS-injected controls. A significantly lower
plaque burden was observed as well for AβpE3−X and AβX−40 in the anterior mo-
tor cortex of the NT4X-167 group when specific antibodies were employed to further
characterize the nature of the amyloid deposits. The 1-57- and 9D5 group showed un-
altered plaque levels. In the thalamus, the observed differences in the plaque load were
not significant, although the lower average levels of Thioflavin S-positive plaques and
AβX−40/ AβpE3−X immunoreactiviy indicate a trend in line with the finding of re-
duced plaque burden in the anterior motor cortex. It might be that the thalamus is less
accessible to administered antibodies for some reason, or that the plaque deposition
follows a different pattern. (Frost et al., 2012), wo reported lesser treatment effects in
certain brain regions such as the cerebellum, discussed similarly.
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Plaque abundance and plaque deposition in the brain are linked to soluble Aβ
(DeMattos et al., 2002; Hong et al., 2011; Koffie et al., 2009), and further soluble protofib-
rillar Aβ was correlated with spatial learning in an AD mouse model (Lord et al.,
2009a). Nevertheless, according to the modified amyloid hypothesis plaques might still
function as a source for soluble peptides. Targeting plaques directly can therefore be
considered an approach to reduce a potential secondary source or reservoir of soluble/
intracellular Aβ, whereas a direct engagement with the soluble peptide fraction would
prevent further plaque deposition.
In mid stage treatment approaches such as the present study, antibody-mediated re-
moval of pre-existing plaques must be sufficient to exceed the amount of newly de-
posited amyloid or the administered antibody must prevent deposition of soluble Aβ
efficiently enough to induce significant differences at the time of analysis or the anti-
body must be capable to exert activity serving both mechanisms, leading to an overall
reduced plaque burden. This probably explains the observed less robust treatment ef-
fects compared to previous studies (Bard et al., 2000; DeMattos et al., 2001, 2012; Frost
et al., 2012) and might provide further explanation for the observation that the appar-
ently lower plaque burden in the thalamus of NT4X-167 injected animals did not reach
significance.
Here, NT4X-167 was the only antibody whose administration decreased fibrillar and
total Aβ deposits, especially N-truncated and pyroglutamate-modified Aβ in the cortex
of 5XFAD mice. This indicates that passive immunization with NT4X-167 is efficacious
in modulating the amyloid pathology, whereas treatment against total (antibody 1-57)
or oligomeric AβpE3−X (antibody 9D5) alone did not reveal such an effect. However,
this results are somehow controversial: It has been published before that the admin-
istration of antibodies specific for AβpE3−X had effects on either the amount of over-
all levels of Aβ measured by ELISA on brain lysates (PDAPP model, DeMattos et al.
(2012)) or reduced AβpE3−X-positive plaque load (APPswe/∆E9 model, Frost et al.
(2012)). In addition, Wirths et al. (2010c) reported that chronic passive administration
of the antibody 9D5 to 5XFAD reduced overall plaque load for general Aβ, AβX−42,
AβX−40 as well as for AβpE3−X; furthermore the authors reported reduced levels of
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AβpE3−X in the soluble and insoluble fraction of whole brain lysates and an ameli-
orated behavioral impairment after 6 weeks of treatment. Different aspects of these
findings will be discussed in the following:
Lack of Plaque-lowering Effects in the 9D5 and 1-57 Groups
The results for the 9D5 group were strikingly deviant from Wirths et al. (2010c), who
reported that treatment with 9D5 resulted in reduced plaque load in the treatment
group compared to PBS-injected animals. Therefore, one could expect at least halting
or a slow-down of amyloid deposition in the current study, in particular if oligomeric
AβpE3−X promotes plaque deposition by a seeding mechanism (Wittnam et al., 2012).
It might be that a considerably different protocol (prolongation of the treatment) com-
pared to Wirths et al. (2010c) leads to the finding that effects of passive immunization
are masked by an overall fast progression of the pathologic alterations. This would
suggest that the treatment was capable of slowing down, but not of preventing the
pathologic alterations in Wirths et al. (2010c), and treated animals catch up phenotyp-
ically with untreated controls during a prolonged immunization protocol. Considering
that Aβ4−X, which was not targeted in Wirths et al. (2010c), precedes AβpE3−X in
5XFAD (Antonios et al., 2013) and might substantially contribute to trigger the patho-
logic cascade, targeting AβpE3−X alone is probably not sufficient to cause persisting
treatment effects.
Diverging methodologic procedures are another possible explanation for different
study outcomes. The antibodies employed here for plaque load quantification were,
except G2-10, others than those employed in Wirths et al. (2010c). Therefore, results of
the current study allow for comparison between the treatment groups but comparison
with previous studies is complicated due to methodologic divergence. However, the
results obtained in both studies on 9D5 for the three analytical parameters, i.e. plaque
load, levels of insoluble Aβ in brain lysates and behavioral performance, were well in
line with each other. This consistency within the individual studies indicates that phen-
otypical inter-animal variability needs to be taken into consideration, too. Both studies
analyzed a relatively small number of animals (n = 4 per group in Wirths et al. (2010c);
n = 7-8 here), therefore the statistics need to be interpreted with care.
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These factors might to some extent account for the observed discrepancy between the
two studies. However, it has been shown here that when acting on both major N-
truncated Aβ isoforms, a treatment effect becomes visible, which further supports
the importance of Aβ4−X. NT4X-167 recognizes both AβpE3−X and Aβ4−X which
probably makes it more capable of recognizing hetero-Aβ-assemblies containing N-
truncated Aβ, improving its efficacy. NT4X-167 recognizes soluble oligomers and a
subset of amyloid plaques and it shows a slight preference for the more soluble Aβ4−40
(Antonios et al., 2013).
Whereas 1-57 strongly recognizes plaques in human and murine brain samples (Wirths
et al., 2010a), NT4X-167 barely reacted with human AD plaques but with amyloid
deposits in transgene mouse brains (Antonios et al., 2013). This points to important
structural differences between plaques of human AD and to a preference of NT4X-
167 for rather soluble or less-dense amyloid strucutures, probably promoted by the
conformational properties of Aβ4−X. Major structural differences between human and
murine plaques have been described by Kuo et al. (2001), who reported that the human
plaque cores were highly resistant to chemical and physical disruption whereas murine
(APP23) plaques were completely soluble in SDS-containing buffers. In addition to the
apparently different target engagement of NT4X-167 in human and murine samples,
an apparent preference of Aβ4−40 over Aβ4−42 gives further indication that NT4X-167
might preferentially bind to more soluble Aβ assemblies (Antonios et al., 2013).
In vitro experiments suggested that intracellular Aβ aggregates released from the
endosomal/lysosomal system are capable to induce Aβ fibrillization (Friedrich et al.,
2010; Hu et al., 2009). It has further been demonstrated that PBS-soluble fractions from
AD brains are efficiently inducing amyloid deposition when administered in murine
brains (Fritschi et al., 2014b). The lower engagement of NT4X-167 with highly ag-
gregated, more degradation-resistant amyloid deposits and on the contrary a better
recognition of soluble oligomers might provide explanation for the efficacy of treat-
ment with NT4X-167 compared to 1-57 treatment. Furthermore might differences in
antibody binding capacity, the recognition of assemblies composed of more than one
Aβ isoform (hetero-oligomers/fibrils) and the accessibility/abundance of epitopes and
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neo-epitopes as well as the immunodetection protocol influence the outcome of quant-
itative measures.
However, the results found here for the 1-57 immunized group are somehow in line
with the prevention trial reported in DeMattos et al. (2012) (antibody mE8). In both
approaches, anti-AβpE3−X-antibodies, both recognizing plaques, were employed, but
mE8 detected only 0.6 % of all Aβ found in AD and PDAPP mouse brains.
DeMattos et al. (2012) further claim that mE8 is plaque-specific, whereas 1-57 engages
with soluble and deposited AβpE3−X as shown by Western Blotting (see 3.1, page 57)
and in Wirths et al. (2010a). Similar to the antibody mE8, 1-57 was not capable of alter-
ing plaque levels.
The treatment window chosen for the present study represents a stage of 5XFAD an-
imals well in-between the onset and a possible plateau stage of plaque deposition. It
has been shown that the levels of soluble Aβ is elevated in the vicinity of plaques (Kof-
fie et al., 2009) and in PDAPP is in an equilibrium with the deposited Aβ (DeMattos
et al., 2002). It has further been proposed that this cloud of soluble peptides surrond-
ing plaques acts as a barrier that prevent antibodies to engage with plaques, causing
failure in modulationg plaque pathology. A small 0.1 % fraction of the antibodies in
the periphery crosses the blood brain barrier (Giedraitis et al., 2007; Mehta et al., 2001)
to encounter Aβ in the central nervous system, which is 20 to 67-fold more abundant
in the central nervous system than in the periphery. Therefore, it has been previously
proposed that antibodies can be overwhelmed by the amounts of accessible target. (Das
et al., 2001).
It has been described previously that the efficacy of antibodies in amyloid removal
is dose dependent DeMattos et al. (2012); Schroeter et al. (2008). Alhough the dosage
seems generally well in line with the majority of other passive immunization studies
that reported in vivo-efficacy (see also appendix, table 4.2, pages 115 ff), it might be,
that the dosage was not sufficient for 1-57 to cause a significant effect. DeMattos et al.
(2012) reported significant plaque removal only with 12.5 mg/kg body weight which
is a 25 % higher dose than in the present study. However, a combination of all or some
of these effects could have caused the failure of 1-57 to modulate the pathology.
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No assumptions can be made, however, if 1-57 would be capable of reducing pre-
existing plaques in a trial on mice that reached a plateau stage of plaque deposition.
In contrast to these two studies, Frost et al. (2012) reported a significant plaque-
lowering effect of anti-AβpE3−X passive immunization in both a preventative (starting
before onset of plaque deposition) and a therapeutic trial. DeMattos et al. (2012); Frost
et al. (2012); Wirths et al. (2010c) and the current study taken together do not allow
to draw a profund conclusion. There is good indication that targeting N-truncated Aβ
peptides in vivo is possible and, given the right preconditions, might be capable of mod-
ulating Aβ pathology. However, the considerable differences in the outcome of these
attempts on passive immunization indicate that different approaches lead to divergent
results, as these studies were conducted with different treatment strategies (initiation,
end point, duration), antibodies (specificity, IgG-subtype), dosages, mouse models and
analytical protocols.
Insoluble Amyloid-beta Levels in Brain of 5XFAD Mice after Passive Immunization
When assessing brains of passively immunized mice for insoluble Aβ1−40/42 and
AβpE3−X in SDS-fractions of brain lysates by ELISA, we did not observe any signi-
ficant effect of the treatments (Data not shown; ELISA experiments were performed
by Sandra Baches, Dept. of Neuropathology, Heinrich Heine Universität Düsseldorf,
Germany). The results for Aβ1−42 are well in line with the plaque load measures for
AβX−42 and Aβ1−X where we did not find significant differences among treatment
groups. In contrast to ELISA experiments, the plaque load levels in the anterior motor
cortex were significantly reduced for AβpE3−X and AβX−40 in the NT4X-167 group. It
is not clear, what led to the discrepancy observed between these analyses. One explan-
ation might be that plaque load analysis focuses on distinct regions in thin sections of
brain tissue, whereas the lysate fraction were representing an entire brain hemisphere.
Both experimental approaches analyze different fractions of Aβ: A plaque load quanti-
fication focuses on a particular brain region in contrast to the analysis of whole brain
lysates.
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Moreover contains the SDS-fraction of brain lysates not only Aβ peptides from plaques
but all amyloid aggreagates from the insoluble fractions of the brain tissue. Further-
more were the antibodies used for detection of Aβ in ELISA measurements different
from those taken for plaque load quantification. This might account for important dis-
crepancy as for instance the antibody IC16 was not suitable for plaque load analysis
due to lower contrast observed in stainings compared to stainings with other antibod-
ies such as Aβ[N], whereas it is well established in ELISA for detecting Aβ1−X. Thus,
the suitability of the antibody for a certain methodologic approach seems greatly im-
portant. Previously published studies that reported lowered Aβ levels in brain lysates
followed different analytical protocols and were using other antibodies for detection
than here (Bard et al., 2000; DeMattos et al., 2012; Wirths et al., 2010c).
The unequal methodology might, together with different sample sizes and models
used, account for differential outcomes of measures and statistics. Nevertheless, the ma-
jority of passive immunization studies employed quantification of the amyloid plaque
burden in brain sections of immunized mice as the main analytical parameter (Bard
et al., 2000; DeMattos et al., 2001; Frost et al., 2012; Wilcock et al., 2004b,c, 2006; Wirths
et al., 2010c). As ELISA data are lacking in some of these studies, this indicates that
quantification of plaque burden is well-accepted and might be more robust to determ-
ine effects of passive immunization. The observation that the plaque load after immun-
ization is lowered despite of ELISA measurements showing no significant difference
between groups is, however, consistent with some previously published studies (Frost
et al., 2012; Janus et al., 2000), of which the previous reported similar results in a trial
on an antibody against N-truncated AβpE3−X.
Behavioral Phenotype of 5XFAD Mice after Passive Immunization
Only a subset of studies addressed the question whether a rescue of behavioral or
learning/memory deficits can be achieved by passive immunization against Aβ. No-
ticeably, such rescue or amelioration has been reported for different mouse models,
PDAPP (Dodart et al., 2002), Tg2576 (Wilcock et al., 2004b,c, 2006) and 5XFAD (Wirths
et al., 2010c).
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Within the mentioned studies, different monoclonal antibodies were used, recog-
nizing central Aβ epitopes (Dodart et al., 2002; Wilcock et al., 2004b,c, 2006), and a
conformation-specific antibody (9D5, (Wirths et al., 2010c)) against AβpE3−X, which
has been investigated here as well. As mentioned previously, the outcome of Wirths
et al. (2010c) was strikingly different from the results found here. This held also true
for behavioral performance of treated mice, where, in contrast to the previous study,
no rescue or amelioration of the 9D5 group was observed.
Here, no robust significant difference to the PBS-controls was observed for the NT4X-
167, 1-57 or 9D5 groups in the Elevated Plus Maze and the Cross Maze paradigms
but, however, a trend towards an amelioration of working memory impairment in the
NT4X-167 group in the cross maze was observed.
However, it must be stated that the pathologic alterations in the 5XFAD model
are still in progress at the age of 6 months (endpoint of treatment in Wirths et al.
(2010c)), with the plaque burden increasing by approximately 2-fold between both 3-6
months and 6-12 months of age (Jawhar et al., 2012). Our experiments performed on
5XFADhom animals showed that even a 2-fold increase of the transgene dose would
not lead to a plateau stage in plaque deposition before the age of 9 months (Richard
et al., 2015). Robust spatial memory deficits are not present until the age of 7 months
(Richard et al., 2015), but have been described as late as at the age of 12 months in
5XFADhem mice bred on a C57Bl6/J genetic background (Bouter et al., 2014). Accord-
ing to the modified amyloid cascade hypothesis, intracellullar Aβ peptides trigger a
fatal cascade of secondary events that lead to behavioral and memory deficits. Intracel-
lular Aβ is evident as early as at the age of 6 weeks in the 5XFAD model. Bouter et al.
(2014) thoroughly investigated the molecular profile of plaques, memory decline and
neuron loss in 5XFAD. The authors found 19 differently expressed genes in young (3-6-
month-old) 5XFAD, which were mainly associated with inflammatory processes. Thus,
the pathologically Aβ-triggered cascade is likely to be already ongoing at the starting
point of the study, which probably interferes with reverting or halting a progressing
development of behavioral symptoms.
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Furthermore, it is likely that the pathological alterations in the mouse model do not
exclusively rely on N-truncated Aβ. AβX−42 exerts similar neurotoxicity as AβpE3−42
and Aβ4−40/42 in vitro (Bouter et al., 2013). Therefore it is conceivable that the major
fraction of Aβ1−42 (and probably other species found in 5XFAD), which is not directly
targeted, contributes significantly to induce behavioral alterations. Importantly, the Aβ
pool in 5XFAD brain comprises much less N-truncated Aβ than in AD patients brain,
where those represent a major fraction (Kawarabayashi et al., 2001; Portelius et al., 2010;
Saido et al., 1995). 5XFAD accumulates predominantly N-terminally intact Aβ in neur-
onal cells that are prone to degenerate at 12 months (Antonios et al., 2013; Jawhar et al.,
2012; Oakley et al., 2006).
Apparently in line with this hypothesis, various studies reported amelioration of be-
havioral and/or learning/memory deficits after administration of pan-Aβ antibodies
recognizing central epitopes within the Aβ sequence (Dodart et al., 2002; Wilcock
et al., 2004b,c, 2006). These antibodies bind well to the (in models) highly abundant N-
terminally intact isoforms, which suggests that the observed treatment effects are not
merely based on removal of N-truncated Aβ. Thus, given a key role for N-truncated
Aβ, it can be hypothesized that immunotherapy targeting these isoforms would have
better potential to alleviate or slow down the progression of cognitive deficits in pa-
tients or models that show higher levels of, or are exclusively expressing N-truncated
Aβ isoforms.
The mean alternation rates of the WT and the NT4X-167 group were similar, but a
comparison between the NT4X-167- and the PBS group did only reveal a positive trend
that was overall not significant. This has to be interpreted with care into each direction,
since the number of animals per group was relatively low. Inter-individual variation
within small samples might therefore account for the observed discrepancy between
the present study and Wirths et al. (2010c). It remains unclear if passive immunization
with NT4X-167 can have effects on behavior/memory.
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Nevertheless, comparison of the three treatment groups in the present studies indic-
ates that, depending on the choice of the antibody/target for immunotherapy, there is a
possibility to modify pathology in a mid-stage therapeutic approach. The lower plaque
load measures in the NT4X-167 group, and the corresponding higher rate of correct
alternations in the same group seem to support each other.
4.4.2 Mechanism of Action of Anti-amyloid-beta Immunization
Several hypotheses have been proposed for the mechanism of action of anti-Aβ an-
tibodies in anti-Aβ-immunization. It has been shown that a small subset (0.1 %) of
peripheral antibodies enter the central nervous system through the blood brain barrier
(Pan et al., 2002), a finding that implies the possibility of antibody-mediated effects oc-
curing by direct interaction with Aβ in the brain. Thus, one of three main hypotheses
is that opsonization of antigens upon antibody recognition triggers phagocytosis by
macrophages/microglia. This mechanism requires sufficient levels of antibodies in the
brain after administration. Support for this hypothesis comes from studies that found
abundant antibody-decorated plaques and increased microglial activity after immuniz-
ation (Bard et al., 2000; DeMattos et al., 2012; Wilcock et al., 2004a,b, 2006). Clearance
of pre-existing plaques after passive immunization has been credibly demonstrated in
a murine model by Wang et al. (2011), in which the authors further support that mi-
croglial phagocytosis is involved in the observed plaque removal. DeMattos et al. (2012)
discussed that antibodies might be hindered from altering plaques by saturation with
soluble peptides in the vicinity of extracellular aggregates, thereby failing to trigger
phagocytosis-dependent plaque removal.
However, it was earlier described that engagement of antibodies with soluble Aβ is
not predictive of the antibodies´ in vivo efficacy (Bard et al., 2000) and others repor-
ted that the phagocytosis effector funciton is not essential to modulate Aβ pathology
(Bacskai et al., 2002; Das et al., 2003). It was proposed that peripherally circulating anti-
bodies might facilitate Aβ clearance from the brain through a so-called peripheral sink
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mechanism, neutralizing circulating peptides and thereby shifting the Aβ equilibrium
towards a higher efflux/reduced influx through the blood brain barrier (Bacskai et al.,
2002; Das et al., 2003; DeMattos et al., 2001). Supporting this view, it has been shown
that Aβ can be rapidly transported to the periphery (Ghersi-Egea et al., 1996; Shibata
et al., 2000; Zlokovic et al., 1993, 1994, 1996).
A third mechanism possibly explaining a treatment effect of anti-Aβ antibodies is
blocking of peptides by the mere molecular interaction, thereby preventing cytotoxicity,
nucleation/seeding and/or conformational imprinting, mechanisms to which patholo-
gic activity of Aβ has been attributed in numerous studies (Fritschi et al., 2014a,b;
Nussbaum et al., 2012; Schlenzig et al., 2009). Catalytic activity of antibodies has been
suggested by Solomon et al. (1996, 1997) and has further been supported by others
(Adolfsson et al., 2012; Alcantar et al., 2010).
Of note, none of these proposed mechanisms are mutually exclusive. However, the
present study focused on comparison of three antibodies in regarding their targets.
Differential phagocytosis effector function was ruled out by the choice of antibodies
of the same isotype (IgG2b) and the mid-stage treatment approach does not allow for
discrimination between different mechanisms of action of the administered antibodies.
To this end, additional experiments would be necessary.
4.4.3 Therapeutic Advantage with NT4X-167?
It is not clear to which extent the phenotypical alterations in 5XFAD can be attributed to
N-truncated AβpE3−X/ Aβ4−X, although several recent in vivo studies from our labor-
atory have provided evidence that N-truncated Aβ isoforms are indeed connected with
behavior deficits and memory impairment (Alexandru et al., 2011; Bouter et al., 2013;
Wirths et al., 2009; Wittnam et al., 2012). There is further indication that a treatment
effect can be achieved with antibodies targeting AβpE3−X (DeMattos et al., 2012; Frost
et al., 2012). However, in the present study it was found that two anti-AβpE3−X anti-
body (1-57) had no significant treatment effects.
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To rank the therapeutic potential of different antibodies/targets, it is of importance to
conduct comparative approaches. The setup of the present comparative study rules out
the bias of varying analytical methods, different models, and different IgG subtypes of
antibodies. Therefore the different efficacy of treatments can be attributed to the an-
tibodies´ target engagement and the results can in return give good indication if the
addressed target is suitable for therapy.
The study conducted here offers the advantage of a scenario close to preclinical or
early-stage AD. However, the obtained effetcs were less pronounced than in previous
studies (DeMattos et al., 2012; Frost et al., 2012; Wirths et al., 2010c).
The observation that passive immunization against AβpE3−X alone was not capable
of inducing treatment effects here indicates that Aβ4−X significantly contributes to
the neuropathologic phenotype in the 5XFAD model. In contrast to the 1-57- and the
9D5 group, The treatment group that received NT4X-167 revealed significant plaque-
lowering effects in an approach close to preclinical AD. Furthermore, the NT4X-167
treatment group was the only one that showed a positive trend in working memory per-
formance. As pointed out above, comparison beetwen the available studies of a chronic
passive immunization against N-truncated Aβ is restricted due to varying setups of
these studies.
Hence, the main conclusion must be drawn from the comparative approach conduc-
ted here. These results suggest that targeting a broader pool of N-terminally truncated
Aβ, as with the antibody NT4X-167, might posess therapeutic advantage. In turn, this
would rather qualify NT4X-167 than 1-57/9D5 as a therapeutic tool. This observation
is, to date, unique and might give implications for developing a therapeutic strategy in
AD .
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4.5 conclusion/limitations of the study
Here, it was shown that passive immunization against AβpE3−X and Aβ4−X, of which
the latter is found intracellularly at early time points in the 5XFAD model, had signific-
ant effects on the plaque load of passively immunized mice. On the contrary, immun-
ization against AβpE3−X alone did not have such an effect.
Importantly, effects reported in many passive immunization trials are mainly restric-
ted to an amelioration of the Aβ-pathology assessed by means of plaque load and/or
Aβ quantification. Reports of behavioral improvement are few and several models fre-
quently employed for such preclinical studies feature no neuron loss. Consequently,
rescue of neuron loss upon passive immunization has not been described in these
models. Other parameters such as behavior/memory perfomance of transgenic mice
have not been commonly asessed, too. The present study has not aimed to determine a
possible treatment effect on neuron loss and interpretation of behavioral data is restric-
ted due to the relatively low animal number.
As pointed out, the mechanism of action of NT4X-167 in vivo can not be elucidated here.
Although some effects of NT4X-167 on the amyloid plaque burden were observed, it
remains unclear if passive immunization against N-truncated peptide isoforms can
effectuate a robust and persisting improvement of Aβ-induced neurodegenerative al-
terations. Translation of preclinical anti-Aβ immunization studies into clinics has been
proven difficult (Lannfelt et al., 2014). Therefore no prediction for a clincal study on
anti-AβpE3−X/ Aβ4−X immunotherapy can be made.
In summary, the data obtained here have further validated the 5XFAD mouse model
for analysis of N-truncated Aβ, behavior and memory. The passive immunization pilot
study conducted provides a proof of the concept that Aβ4−X is accessible for passive
immunotherapy in vivo and in turn indicates that NT4X-167 has therapeutic advantage
over other antibodies targeting N-truncated Aβ. The suitability of the 5XFAD model
for research on N-truncated Aβ isoforms is further supported.
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Please note: Metric prefixes and units described in the International System of Units
(SI) are not listed here.
Aβ Amyloid-beta peptide
AβX1−X2 Amyloid-beta peptide ranging from N-terminal amino acid X1 to
C-teminal amino acid X2
AD Alzheimer´s disease
ANOVA Analysis of Variance
APP Amyloid-Precursor-Protein
BSA Bovine serum albumin
CAA Cerebral Amyloid Angiopathy
IP Immuno-Precipitation
MALDI-TOF Matrix-Assisted Laser Desoption/Ionisation - Time of Flight
NaOH Sodium hydroxide








SDS Sodium dodecyl sulfate
TBS Tris-buffered saline
TBS-T Tris-buffered saline supplemented with Tween-20
Tris Tris(hydroxymethyl)-aminomethane
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